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Abstract 
Linear cationic β-cyclodextrin (β-CD)-based polymers can bind with plasmid 
DNA to form colloid-sized composite particles (denoted as polyplexes) that are able to 
transfect cultured cells.  The effectiveness of gene delivery and the cellular toxicity have 
been related to structural features of the polycation.  β-CD polycations are prepared by 
the co-condensation of 6A,6D-dideoxy-6A,6D-diamino-β-CD monomers with other 
difunctionalized monomers such as dimethylsuberimidate (DMS).  In the first part of this 
thesis, synthetic variations of the β-CD structure are used to probe structure-function 
gene delivery properties.  The type of cyclodextrin and its functionalization are 
investigated by synthesizing numerous 3A,3B-dideoxy-3A,3B-diamino-β- and γ-CD 
monomers.  Both alkyl- and alkoxy-diamines are prepared in order to vary the nature of 
the spacing between the CD and the primary amines in the CD monomers.  These 
diamino-CD-monomers are polymerized with DMS to yield amidine-based polycations.  
The nature of the spacer between the CD-ring and the primary amines of each monomer 
is found to influence both molecular weight and polydispersity of the polycations.  When 
these polycations are used to form polyplexes with plasmid DNA, longer alkyl regions 
between the CD and the charge centers in the polycation backbone increase transfection 
efficiency and toxicity in BHK-21 cells, while increasing the hydrophilicity of the spacer 
(alkoxy versus alkyl) provides for lower toxicity.  Further, γ-CD-based polycations are 
shown to be less toxic than otherwise identical β-CD-based polycations.  
 Linear, cyclodextrin-based gene delivery systems, such as those described in the 
first part of this thesis, are amenable to forming polyplexes with a wide range of 
physicochemical properties that include size, surface charge, and density and type of 
 vii
ligand presented.  However, it is not known how to best design these particles without 
having a set of physicochemical design constraints that have been optimized for the 
intended gene-delivery application.  In the second part of this thesis, I developed a model 
delivery system that can mimic the surface properties of the cyclodextrin-based gene-
delivery particles and used it to define design constraints that should be applied to next 
generation gene delivery particles.  As a test case, a well-defined nanoparticle-based 
system is developed to guide the rational design of gene delivery to hepatocytes in the 
liver.  The synthetic scheme allows for the variation of mean particle size and particle 
size distribution through variation in reaction conditions.  The nanoparticle synthesis is 
also amenable to incorporation of various ligand types, e.g., galactose, at tunable 
densities.  The synthesized nanoparticles are further shown to have PEGylated surfaces 
that resist aggregation in serum.  Finally, the availability of galactose to receptor binding 
is demonstrated by agglutination with RCA120. 
Four nanoparticles are synthesized specifically for the purpose of identifying 
design constraints to guide next generation gene delivery to the liver.  These 
nanoparticles are synthesized and described:  Gal-50 and Gal-140 are galactosylated 50 
nm and 140 nm nanoparticles, while MeO-50 and MeO-140 are methoxy-terminated 50 
nm and 140 nm nanoparticles.  All four particles have the same surface charge, and Gal-
50 and Gal-140 have the same surface galactose density. 
The hepatocyte uptake in vitro and hepatic distribution in vivo of these four 
nanoparticles is investigated.  In freshly isolated hepatocytes, Gal-50 nanoparticles are 
taken up to a greater extent than are MeO-50, but both 50 nm beads are taken up to a 
much greater extent than are either of the 140 nm nanoparticles.  However, about 90% of 
 viii
the in vivo dose of Gal-140 nanoparticles is found within the liver 20 minutes after tail-
vein injection.  TEM and immunohistochemistry images confirm that Gal-140 
nanoparticles are primarily internalized by Kupffer cells, though isolated examples of a 
few Gal-140 in hepatocytes can also be found.  On the other hand, Gal-50 nanoparticles 
are overwhelmingly found in vesicles throughout the cytoplasm of hepatocytes, with only 
isolated examples of Kupffer cell uptake.  Despite similar surface charge and ligand 
density, 50 nm nanoparticles are primarily found in hepatocytes while 140 nm 
nanoparticles are primarily seen in Kupffer cells.  It is therefore clear that slightly 
anionic, galactose-PEGylated nanoparticles should be about 50 nm in diameter to 
preferentially target hepatocytes while they should be about 140 nm in diameter to 
selectively target Kupffer cells. 
 
 ix
Table of Contents 
 
Acknowledgements............................................................................................................ iv 
Abstract .............................................................................................................................. vi 
Table of Contents............................................................................................................... ix 
List of Figures ................................................................................................................... xii 
List of Schemes................................................................................................................. xv 
List of Tables ................................................................................................................... xvi 
 
Chapter One:  Introduction and Organization of Thesis Presentation ....................... 1 
 
Chapter Two:  Structural Effects of Carbohydrate-Containing Polycations on Gene 
Delivery. 3. Cyclodextrin Type and Functionalization.................................................. 5 
2.1  Introduction.................................................................................................................. 6 
2.2  Materials and Methods................................................................................................. 8 
2.2.1  Synthesis of Benzophenone-3,3’-disulfonyl Chloride (1, Scheme 2.1)................ 9 
2.2.2  Synthesis of Benzophenone-3,3’-disulfonyl Imidazole (2, Scheme 2.1)............ 10 
2.2.3  Synthesis of Cyclodextrin-polycations (6a-d and 7a-d, Scheme 2.2). ................ 10 
2.2.4  Light Scattering and Molecular Weight Determination...................................... 12 
2.2.5  Plasmid DNA...................................................................................................... 13 
2.2.6  Polyplex Formation and Characterization. ......................................................... 13 
2.2.7  Cell Culture and Transfections ........................................................................... 14 
2.3  Results........................................................................................................................ 15 
2.3.1  Polycation Synthesis and Characterization......................................................... 15 
2.3.2  Polyplex Formation and Characterization .......................................................... 16 
2.3.3  In Vitro Transfection Efficiency ......................................................................... 17 
2.3.4  In Vitro Cellular Toxicity.................................................................................... 19 
2.4  Discussion .................................................................................................................. 21 
2.5  Acknowledgements.................................................................................................... 26 
2.6  References.................................................................................................................. 26 
 
Chapter Three:  Introduction to Part Two................................................................... 30 
3.1  Introduction................................................................................................................ 31 
3.2  Liver Structure and Physiology ................................................................................. 31 
3.3  Diseases of the Liver.................................................................................................. 38 
3.4  Gene Delivery to the Liver ........................................................................................ 40 
3.5  References.................................................................................................................. 43 
 
Chapter Four:  Synthesis and Characterization of a Model Delivery System to 
Guide the Rational Design of Gene Delivery to the Liver ........................................... 48 
4.1  Introduction................................................................................................................ 49 
4.2  Materials and Methods............................................................................................... 50 
4.2.1  Synthesis of Galactose-PEG5000-amine (1, Scheme 4.1) .................................... 51 
4.2.2  Synthesis of PEGylated-polystyrene Nanoparticles (2, Scheme 4.2) ................. 52 
4.2.3  Particle Size and ζ-potential Measurements ....................................................... 53 
4.2.4  Determination of Galactose Surface Density...................................................... 54 
 x
4.2.5  RCA120 Lectin Agglutination.............................................................................. 54 
4.2.6  TEM of Nanoparticles......................................................................................... 55 
4.2.7  Serum-Induced Nanoparticle Aggregation ......................................................... 55 
4.3  Results and Discussion .............................................................................................. 55 
4.3.1 Gal-PEG5000-NH2 Synthesis and Characterization............................................... 55 
4.3.2  PEGylated Nanoparticle Synthesis and Characterization ................................... 59 
4.3.3  Availability of Galactose for Receptor Binding ................................................. 63 
4.3.4  Description of Nanoparticles for Uptake Studies ............................................... 68 
4.3.5  Serum Aggregation of PEGylated Nanoparticles ............................................... 69 
4.4  Conclusions................................................................................................................ 71 
4.5  References.................................................................................................................. 71 
 
Chapter Five:  Relationship Between Physicochemical Properties and Hepatic 
Distribution and Uptake of PEGylated Nanoparticles ................................................ 76 
5.1  Introduction................................................................................................................ 77 
5.2  Materials and Methods............................................................................................... 79 
5.2.1  Animals ............................................................................................................... 79 
5.2.2  Hepatocyte Isolation ........................................................................................... 80 
5.2.3  Nanoparticle Uptake by Adherent Hepatocytes.................................................. 81 
5.2.4  Preparation of Suspended Hepatocytes............................................................... 82 
5.2.5  Flow Cytometry Analysis of Nanoparticle Uptake Kinetics .............................. 82 
5.2.6  Bulk Liver Uptake of Nanoparticles ................................................................... 83 
5.2.7  TEM Imaging of Liver Tissue ............................................................................ 84 
5.2.8  Overlay of Fluorescence and TEM iImages ....................................................... 84 
5.2.9  Immunohistochemical Staining .......................................................................... 85 
5.2.10  Immunohistochemistry Imaging ....................................................................... 86 
5.3  Results and Discussion .............................................................................................. 86 
5.3.1  In Vitro Uptake Results....................................................................................... 86 
5.3.2  Optimization of Experimental Conditions for In Vivo Experiments .................. 91 
5.3.3  Bulk Liver Uptake of Nanoparticles ................................................................... 93 
5.3.4  TEM Imaging Following Tail-Vein Injection of Nanoparticles ......................... 94 
5.3.4.1  Hepatic Distribution of 140 nm Nanoparticles ............................................ 95 
5.3.4.2  Hepatic Distribution of 50 nm Nanoparticles .............................................. 97 
5.3.5  Immunohistochemistry Following Tail-Vein Injection of Nanoparticles......... 101 
5.4  Conclusions.............................................................................................................. 108 
5.5 Acknowledgements................................................................................................... 109 
5.6  References................................................................................................................ 109 
 
Chapter Six:  Overall Conclusions, Recommendations and Future  
Considerations............................................................................................................... 114 
6.1  Overall Conclusions and Recomendations .............................................................. 115 
6.2  Future Consideration: Increased ligand Specificity................................................. 116 
6.3  Future Consideration: Variation in Surface Density of Ligand ............................... 121 
6.4  References................................................................................................................ 122 
 
 
 xi
Appendices..................................................................................................................... 126 
Appendix A:  Galactose Surface Concentration Determination ..................................... 127 
Appendix B:  Nanoparticle Exocytosis by Freshly Isolated, Cultured Hepatocytes ...... 129 
B.1  References ........................................................................................................... 131 
Appendix C:  Isolation of Non-Parenchymal Liver Cells after Nanoparticle Injection . 132 
C.1  References ........................................................................................................... 134 
Appendix D:  Effect of Nanoparticle Dose on Uptake by Suspended Hepatocytes ....... 135 
D.1  References........................................................................................................... 137 
 
 
 xii
List of Figures 
Figure 2.1.  Representations and labeling of β-cyclodextrin ............................................. 7 
Figure 2.2. Agarose gel electrophoresis of polycation/pDNA complexes.  For each 
polycation, complexes were formulated at charge ratios (+/-) of 0, 0.5, 1.0, 1.5, 2.0, 2.5 
and 3.0 and run in order of increasing charge ratio (left to right) on a 0.8% agarose  
gel...................................................................................................................................... 15 
 
Figure 2.3.  Relative light units (RLU)/mg protein as a function of charge ratio for 
cyclodextin-polycation/pDNA complexes.  Complexes were formulated at various charge 
ratios and exposed to BHK cells in serum-free medium for four hours.  48 hours after 
exposure, the cells were assayed for luciferase activity.  Charge ratio of 0 indicates naked 
pDNA................................................................................................................................ 18 
 
Figure 2.4.  Cell viability to exposure of polycation/pDNA complexes at various charge 
ratios.  Cells were assayed for viability 48 hours after exposure to complexes; data were 
normalized with respect to untreated cells........................................................................ 19 
 
Figure 2.5.  Comparison of the toxicity of polycation alone to polycation/pDNA 
complexes.  Cells were exposed to polycation alone or to an equal amount of polycation 
complexed with pDNA; “charge ratio” for polycation alone merely represents amount of 
polycation.  Total protein concentrations in cell lysates were used as a measure of 
viability; data were normalized using values for untreated cells ...................................... 20 
 
Figure 3.1.  Illustration of liver structure.  Reproduced with permission from Novartis 
Pharmaceuticals Corporation.  Circles point out mixing of blood flow from the hepatic 
artery with blood flow from the portal vein...................................................................... 32 
 
Figure 3.2.  TEM image of 20 nm thick section of normal mouse liver.  ‘H’ indicates a 
hepatocyte nucleus, ‘K’ indicates a Kupffer cell nucleus, ‘R’ labels a red blood cell, ‘S’ 
labels a sinusoid and ‘E’ points to an endothelial cell lining the sinusoid ....................... 33 
 
Figure 3.3.  TEM image of 20 nm thick section of normal mouse liver, showing liver 
sinusoidal endothelial cells separating hepatocytes from the blood vessel ...................... 35 
 
Figure 3.4.  TEM image of 20 nm thick section of normal mouse liver, showing liver 
sinusoid, liver sinusoidal endothelial cells (‘E’) and space of Disse (‘SoD’) .................. 37 
 
Figure 4.1.  HPLC spectra of a) Fmoc-PEG5000-COOH and b) Gal-PEG5000-NH2.......... 56 
Figure 4.2.  MALDI-TOF mass spectra of a) Fmoc-PEG5000-NHS and b) Gal-PEG5000-
NH2 ................................................................................................................................... 57 
 
 xiii
Figure 4.3.  Mean hydrodynamic diameters following PEGylation of 105 nm 
Fluospheres with different reagent concentrations ........................................................... 60 
 
Figure 4.4.  Histograms of nanoparticle hydrodynamic diameter distributions, as 
measured by PCS in 150 mM NaCl, for a) 50 nm PEGylated polyplexes, b) 50 nm 
PEGylated nanoparticles and c) 140 nm PEGylated nanoparticles .................................. 61 
 
Figure 4.5.  TEM images of a) unmodified 105 nm Fluosphere nanoparticles and b) 
PEGylated 105 nm polystyrene nanoparticles .................................................................. 62 
 
Figure 4.6.  Illustration of nanoparticle agglutination as a result of RCA120 lectin binding 
galactosylated nanoparticles ............................................................................................. 65 
 
Figure 4.7.  Turbidity increase due to agglutination of galactosylated 50 nm 
nanoparticles with RCA120 lectin.  100 µL of 140 mM galactose in PBS is added at 30 
minutes.............................................................................................................................. 66 
 
Figure 4.8.  Turbidity increase of 50 nm nanoparticle with 81.3 pmol/cm2 surface 
galactose density due to agglutination with RCA120 lectin.  100 µL of 140 mM glucose in 
PBS is added at 30 minutes then 100 µL of 140 mM galactose in PBS is added at 35 
minutes.............................................................................................................................. 67 
 
Figure 4.9.  Nanoparticle aggregation in the presence of active mouse serum................ 70 
Figure 5.1.  Kinetics of nanoparticle uptake by suspended hepatocytes, as analyzed by 
flow cytometry.  a) Uptake of 50 nm and 140 nm nanoparticles are shown on the same 
scale.  b) Uptake of 140 nm nanoparticles are shown on an expanded scale ................... 89 
 
Figure 5.2.  Optimization of experimental conditions for in vivo experiments by assaying 
total fluorescence of mouse liver following homogenization of liver and extraction of 
fluorophore.  a) Determination of optimal time between tail-vein injection of 
nanoparticles and liver removal.  8*1011 Gal-50 nanoparticles were injected via tail-vein 
per 20 g mouse, two mice per group, and sacrificed at the time shown.  b) Determination 
of optimal bead dose.  Mice received tail-vein injections of Gal-50 nanoparticles and 
were sacrificed 20 minutes post-injection......................................................................... 92 
 
Figure 5.3.  Overall uptake of nanoparticles into hepatic tissue.  Results are shown as 
mean ± standard deviation of three mice per group.......................................................... 93 
 
Figure 5.4.  TEM images taken of the same 20 nm thick liver section following tail-vein 
injection of 8*1011 Gal-140 nanoparticles per 20 g mouse at scope magnifications of:  a) 
2000x, b) 15,000x and c) 30,000x.  Examples of individual nanoparticles are labeled with 
arrows in b) and c) ............................................................................................................ 95 
 
 xiv
Figure 5.5.  TEM images of hepatocytes following tail-vein injection of a) MeO-50 and 
b) Gal-50 nanoparticles, 8*1011 per 20 g mouse.  Examples of individual vesicles are 
labeled with arrows ........................................................................................................... 97 
 
Figure 5.6.  Comparison of images of the same cell, obtained by a) confocal microscopy 
and b) TEM....................................................................................................................... 98 
 
Figure 5.7.  Imaging of a hepatocyte, 24-hours post isolation that had been exposed to 
Gal-50 nanoparticles.  Comparison of a) light and fluorescence images and b) TEM 
image of the green perinuclear region on the top left side of (a) ...................................... 99 
Figure 5.8.  Illustration of the staining that results from the immunohistochemical 
staining of the hepatic asialoglycoprotein receptor (ASGPr) ......................................... 102 
Figure 5.9.  Immunohistochemistry image of 12 µm-thick section of mouse liver 
following tail-vein injection of 8*1011 MeO-140 nanoparticles.  ASGPr is stained red, 
nuclei are blue and nanoparticles are green/yellow ........................................................ 104 
Figure 5.10.  Immunohistochemistry image of 12 µm-thick section of mouse liver 
following tail-vein injection of 8*1011 Gal-140 nanoparticles.  ASGPr is stained red, 
nuclei are blue and nanoparticles are green/yellow ........................................................ 105 
Figure 5.11.  Immunohistochemistry image of 12 µm-thick section of mouse liver 
following tail-vein injection of 8*1011 Gal-50 nanoparticles.  ASGPr is stained red, nuclei 
are blue and nanoparticles are green/yellow................................................................... 107 
 
Figure A.1.  Calculated surface density of galactose on nanoparticle surfaces by 
comparison to a standard curve of free galactose in solution ......................................... 127 
 
Figure B.1.  Kinetics of exocytosis of nanoparticles from suspended freshly isolated 
hepatocytes...................................................................................................................... 130 
 
Figure D.1.  Effect of nanoparticle dose on uptake into suspended hepatocytes, in media 
containing Cu2+ and Zn2+ ions ........................................................................................ 135 
 
Figure D.2.  Effect of bead concentration on mean fluorescence of suspended primary 
hepatocytes...................................................................................................................... 136 
 
 
 xv
List of Schemes 
Scheme 2.1.  Synthesis of Benzophenone-3,3’-disulfonyl Imidazole................................ 9 
Scheme 2.2.  Synthesis of Cyclodextrin-polycations ....................................................... 12 
Scheme 4.1.  Synthesis of Galactose-PEG5000-NH2 ......................................................... 52 
Scheme 4.2.  Synthesis of PEGylated nanoparticles ........................................................ 53 
Scheme 6.1.  Synthesis of GalNAc-carboxylic acid ligand.  Reagents:  (a) TMSOTf, (b) 
TMSOTf, (c) H2/Pd/EtOAc and (d) NaOMe ................................................................. 119 
 
 
 
 
 
 xvi
List of Tables 
Table 2.1.  Effect of cyclodextrin comonomer structure on polymerization ................... 15 
Table 2.2.  Particle sizing and zeta-potential of polycation/pDNA complexes formulated 
at charge ratio (+/-) of 5 .................................................................................................... 17 
 
Table 4.1.  Molecular weights of Fmoc-PEG5000-NHS and Gal-PEG5000-NH2 for 
incremental numbers of ethylene oxide repeat units, with sodium counterion for 
comparison to peaks of MALDI-TOF spectra .................................................................. 58 
 
Table 4.2.  50 nm PEGylated nanoparticles with different surface densities of galactose 
for use in RCA120 agglutination assay .............................................................................. 64 
 
Table 4.3.  Summary of physicochemical properties of the four nanoparticles to be used 
in uptake experiments ....................................................................................................... 68 
 
Table 5.1.  Summary of physicochemical properties of the four nanoparticles to be used 
in uptake experiments ....................................................................................................... 77 
 
Table 5.2.  In vitro uptake of nanoparticles by freshly isolated hepatocytes, as quantified 
by the overall fluorescence of cell lysates by comparison to a standard curve also using 
hepatocyte lysates ............................................................................................................. 88 
 
Table B.1.  Effect of wash buffer temperature on dose of nanoparticles following 
incubation with freshly isolated hepatocytes.  After removal of nanoparticle-containing 
media, wash buffer of either 37OC or 2OC was incubated on the plated cells for 5 minutes.  
Wash buffer was then removed, cells were lysed and fluorescence of cell lysate was 
compared to standard curves of nanoparticles in unadulterated hepatocyte lysate ........ 129 
 
Table C.1.  Fraction of nanoparticle-containing Kupffer cells after their isolation from 
mouse livers that were exposed to nanoparticles by tail-vein injection of 8*1011 
nanoparticles per 20 g Balb/c mouse .............................................................................. 132 
 
 
 
 
 
 1
 
 
 
 
CHAPTER ONE 
 
 
 
 
INTRODUCTION AND ORGANIZATION OF THESIS PRESENTATION 
 
 
 
 2
Gene therapy involves the manipulation of cellular gene expression in such a way 
that it will be corrective to the patient but not inherited to the next generation.  Gene 
therapy promises to revolutionize the clinical treatment of countless genetic disorders in 
decades to come, but human gene therapy today is still in its infancy.  For clinical gene 
therapy to become commonplace, improvements must be made in the design of gene 
delivery vectors to improve gene expression efficiency, as well as in the overall 
physicochemical properties of the gene delivery particles to improve target selectivity.  
This thesis addresses issues aimed at improving the prospects of gene therapy.  
This thesis is composed of two separate parts.  In the first part, synthetic 
variations of linear, cyclodextrin-based polycations are used to probe structure-gene 
delivery properties.  The synthesis and characterization of new cyclodextrin-polycations 
are described, followed by the results of in vitro assays that allow for the elucidation of 
structure-function relationships.  In particular, the impact of cyclodextrin-type and nature 
of the spacer between the cyclodextrin and the charge center on toxicity and transfection 
efficiency in BHK-21 cells is investigated.  A discussion follows that ties together the 
results and relates this work to other structure-function studies performed in our group. 
Chapter Three through Chapter Six represent Part Two of this thesis.  Part Two 
discusses the development, characterization and results of uptake experiments of a 
nanoparticle-based model system that approximates the physicochemical properties of 
linear, cyclodextrin-based polycations such as those discussed in Part One.   
Chapter Three provides an introduction to gene delivery to the liver.  First an 
overview of liver structure and physiology is presented, along with a number of images to 
clarify the discussion.  A number of liver diseases are then discussed as candidates for 
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treatment by gene therapy, and the potential advantages of gene therapy over 
conventional treatment are outlined.  Specifically targeting non-viral gene delivery 
polyplexes to the desired liver cells to treat these diseases has proved difficult, and the 
importance of developing a nanoparticle-based model system that mimics the surface 
properties of our cyclodextrin-based polyplexes is discussed.  Other requirements of the 
model system are also presented. 
Chapter Four begins with a brief discussion of the importance of PEGylating 
nanoparticle-based systems for in vivo applications and then details the synthesis and 
characterization of the nanoparticles mentioned in Chapter Three.  FITC-embedded 
carboxy-polystyrene nanoparticles were reacted with PEG to form protective coronas that 
shielded any hydrophobic surfaces from contact with other nanoparticles or massive 
protein adsorption from serum.  By careful control of reaction conditions, the mean 
nanoparticle diameter as well as the particle size distribution could be varied and matched 
to the actual size distribution of polyplexes.  Galactose can be conjugated to the 
nanoparticles at different surface densities, and the accessibility of the galactose moieties 
to lectin binding is demonstrated.  Four nanoparticles are described that will be carried 
forward for in vitro and in vivo uptake experiments, which are presented in Chapter Five. 
Chapter Five begins by discussing why freshly isolated hepatocytes were used for 
in vitro experiments instead of commonly used hepatocarcinoma cell lines. A discussion 
of in vitro results follows, in which plated hepatocytes and suspended hepatocytes are 
both utilized.  A set of experimental conditions is then identified that maximizes hepatic 
uptake following injection of nanoparticles.  The effects of dose and time gap between 
injection and liver removal are studied and results are presented.  Once experimental 
 4
conditions are set, the overall uptake of each of the four nanoparticles into hepatic tissue 
is studied and results are discussed.  TEM analysis of liver cross-sections provides 
information on hepatic distribution and intracellular trafficking of the nanoparticles, and a 
number of representative images are presented.  Finally, an immunohistochemical 
staining procedure is developed and introduced by way of illustration on an actual TEM 
image.  Results of these three-color images are discussed and overall conclusions are 
drawn. 
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CHAPTER TWO 
 
 
 
 
STRUCTURAL EFFECTS OF CARBOHYDRATE-CONTAINING POLYCATIONS 
ON GENE DELIVERY. 3. CYCLODEXTRIN TYPE AND FUNCTIONALIZATION 
 
 
 
 
  
 
 
Reproduced with permission from [S. R. Popielarski, S. Mishra and M. E. Davis, 
Bioconjugate Chemistry, 2003, 14, 672-678] 
© 2003 American Chemical Society 
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2.1  Introduction 
Numerous non-viral gene delivery studies are involved in elucidating the 
relationships between vector structure and transfection efficiency by modifying 
promising systems and assaying their performance.  This ongoing research has 
demonstrated the significant influence of polycation structure on the efficiency of gene 
delivery.  Poly(ethyleneimine)s (PEIs) are a widely-studied class of polycations for gene 
delivery.  PEI molecular weight has been shown to affect both cytotoxicity and 
transfection efficiency (1, 2).  The charge density (1) and degree of branching (3) in the 
PEI backbone also significantly alter transfection efficiency in vitro.  Furthermore, 
substituents grafted onto PEI affect the interaction of PEI with DNA as well as PEI/DNA 
polyplex interactions with cells (4-6, and references therein).  Ionenes are another class of 
gene delivery vehicles whose structure has been related to stability of interaction with 
DNA (7) and to transfection efficiency (8).  Structure-function studies have also been 
undertaken with systems based on chitosan (9), poly(L-lysine) (10), linear 
poly(amidoamine)s (11), polysaccharide-oligoamine conjugates (12) and others.  It is 
clear from these reports that minor changes in the structure of the gene delivery vehicle 
can have dramatic effects on the gene delivery efficiency and toxicity of the vector. 
We have prepared families of linear, β-cyclodextrin-containing polycations 
(βCDPs) and have shown that these polymers can be used as gene delivery vectors (13, 
14).  Cyclodextrins (CDs) are cup-shaped molecules formed of cyclic oligomers of 
glucose.  Cyclodextrins comprised of 6, 7 and 8 glucopyranose units are called α-, β- and 
γ-CD, respectively (β-CD is represented in Figure 2.1).  There are three distinct 
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hydroxyls per glucopyranose unit; two secondary carbons and one primary carbon bear 
these hydroxyls and they are labeled C(2), C(3) and C(6), respectively (Figure 2.1).  The 
glucopyranose units are denoted alphabetically starting with ‘A’ and proceeding around 
the cyclodextrin ring (Figure 2.1). 
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Figure 2.1.  Representations and labeling of β-cyclodextrin. 
Initial structure-function studies with βCDPs demonstrated the importance of 
inter-charge spacing to transfection efficiency and toxicity (14).  Significant effects on 
transfection efficiency were observed when the inter-amidine distance was reduced by 
just 2Å.  Based upon this finding, we initiated a more complete structure-function 
investigation using linear, cyclodextrin-containing polycations.  In part 1 of our study, we 
showed that cellular toxicity was related to the distance of the charge center from the 
carbohydrate unit (whether it be a cyclodextrin or trehalose), and that increasing 
polycation hydrophilicity provides decreasing toxicity (15).  Part 2 of our work revealed 
that the type of charge center can dramatically change the delivery efficiency (16).  With 
the βCDPs, amidine charge centers give greater gene delivery than quaternary 
ammonium charge centers.  Here, we vary the type of cyclodextrin (β and γ) and the 
functionalization at the cyclodextrin, i.e., 3A,3B-dideoxy-3A,3B-diamino-β- and γ-CD, as 
compared to the previously used 6A,6D-dideoxy-6A,6D-diamino-β-CD, to prepare a 
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distinct series of linear, cyclodextrin-containing polycations.  Additionally, we report the 
effects of spacer length between the cyclodextrin and the charge center in order to make 
direct comparisons between otherwise identical β- and γ-CD-based polyamidines.  The 
polycations were characterized and assayed for plasmid DNA (pDNA) binding, polyplex 
size and ζ-potential, and in vitro transfection efficiency and toxicity. 
 
2.2  Materials and Methods 
β- and γ-cyclodextrins were purchased from Wacker Biochem Corp. (Adrian, MI) 
and dried in vacuo at 120°C overnight before use.  Chlorosulfonic acid (Alfa Aesar; 
Ward Hill, MA) was distilled before use.  Dimethyl suberimidate•2HCl (DMS) was 
purchased from Pierce Endogen (Rockford, IL) and used without further purification.  All 
other reagents were obtained from commercial suppliers and were used as received.  Ion-
exchange chromatography was run on a Toyopearl SP-650M (TosoHaas; 
Montgomeryville, PA) column (NH4+ form) and products were eluted with aqueous 
ammonium bicarbonate up to 0.4M.  Thin-layer chromatography was performed on Silica 
Gel 60 F 254 plates (EM Separations Technology; Gibbstown, NJ) and the amino-
compounds were eluted with 5:3:3:1 n-PrOH:AcOEt:H2O:NH3(aq) and visualized by 
reaction with ninhydrin.  Matrix-assisted, laser desorption/ionization time-of-flight mass 
spectroscopy (MALDI-TOF-MS) was performed on a PerSeptive Biosystems Voyager 
DE PRO BioSpectrometry Workstation in the positive ion mode using a 2,5-dihydroxy 
benzoic acid matrix. NMR spectra were recorded on a Bruker AMX500 spectrometer as 
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dilute solutions of either D2O or DMSO-d6.  Dialysis was carried out using a 3500 
molecular weight cutoff regenerated cellulose dialysis cassette (Pierce Endogen). 
 
2.2.1  Synthesis of Benzophenone-3,3’-disulfonyl Chloride (1, Scheme 2.1)  
26.06 g (0.143 mol) of benzophenone were added in small portions to 190 mL 
(2.86 mol) of freshly distilled chlorosulfonic acid under an argon atmosphere.  The 
solution was then heated to 120°C with reflux.  After 20 hours at 120°C, the cooled 
solution was added slowly to about 1000 g of ice in a 2L Erlenmeyer flask.  The slurry 
was poured into a separatory funnel then extracted with chloroform (350 mL then 300 
mL) and washed with saturated NaHCO3 (200 ml), water (200 mL) and saturated NaCl 
(200 mL, twice).  The chloroform was removed under reduced pressure.  The yellow 
solid obtained was recrystallized twice from chloroform/hexanes.  The first-crop yielded 
30 g of off-white crystals; thesecond-crop yielded 5.4 g.  (65% yield).  Anal. (C13-
H8Cl2O5S2) C, H, Cl, S. 
O
ClSO3H
O
S SO O O O
Cl Cl
O
Imidazole, Et3N
N
N
N
N
S SO O O O
1200C, 20 hrs 2 hrs
1
2  
Scheme 2.1.  Synthesis of Benzophenone-3,3’-disulfonyl Imidazole (2) 
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2.2.2  Synthesis of Benzophenone-3,3’-disulfonyl Imidazole (2, Scheme 2.1) 
13 g (34.3 mmol) of 1 were dissolved in 150 mL chloroform.  Imidazole (4.95g, 
72.7 mmol) and Et3N (10.2 ml, 73.2 mmol) were added.  After about 30 minutes of 
stirring, 50 mL of dichloromethane were added to the slurry and allowed to stir for an 
additional 30 minutes.  About 200 mL of dichloromethane were required to homogenize 
the reaction slurry, which was then washed with water (200 mL, twice) and dried with 
sodium sulfate.  Benzophenone-3,3’-disulfonyl-imidazole, 2, was recrystallized from 
dichloromethane/ethyl acetate giving 13.9 g of colorless needles (92% yield).  Anal. (C19-
H14N4O5S2) C, H, N, S.  NMR data were in agreement with published chemical shifts 
(17). 
 
2.2.3  Synthesis of cyclodextrin-polycations (6a-d and 7a-d, Scheme 2.2).   
Syntheses of 2A,2B-disulfonated β-cyclodextrin (17) (3a) and 2A,2B-disulfonated 
γ-cyclodextrin (18) (3b) were carried out according to literature methods.  NMR and 
mass spectra data were in agreement with published values (17, 18).  Syntheses of 3A,3B-
di(aminoalkylamino)-β- and 3A,3B-di(aminoalkoxyamino)-γ-cyclodextrins (4a-d and 5a-
d) were carried out as exemplified by the following procedure. 
Synthesis of 5c 
Hexamethylenediamine (5.89 g, 50.7 mmol) was dissolved in 35 mL degassed 
water.  3b (1.50 g, 0.88 mmol) was added at once and stirred at 37OC under nitrogen for 
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19 hours.  The reaction was further carried out at 70OC for 3 hours then concentrated 
under reduced pressure.  Cyclodextrins were precipitated with 11:1 acetone:methanol and 
collected by filtration.  Ion-exchange chromatography yielded the pure product (855 mg, 
54% yield).  MALDI-TOF-MS [M+H]+ = 1493.7. 
The polycations were prepared as exemplified by the following procedure. 
Synthesis of 7c 
5c (100mg, 54.7 µmol) and DMS (15.5 mg, 56.7 µmol) were taken up in 108 µL 
0.5M Na2CO3 and stirred for 13 hours.  Acidification with 1N HCl to pH 2.0 followed by 
exhaustive dialysis yielded 58.4 mg of a white powder (56% yield). 
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Scheme 2.2.  Synthesis of Cyclodextrin-polycations (6a-d and 7a-d). 
 
2.2.4  Light Scattering and Molecular Weight Determination 
The specific refractive index (RI) increment, dn/dc, of each polycation was 
determined by fitting a linear curve to plots of RI versus concentration (five data points 
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per polycation).  Polycations were then analyzed on a Hitachi D6000 HPLC system 
equipped with an ERC-7512 RI detector and a Precision Detectors PD2020/DLS light 
scattering detector using a PL aquagel-OH column (Polymer Laboratories, Amherst, 
MA).  The eluent was 0.8 M ammonium acetate with 0.05% sodium azide, adjusted to pH 
2.8 with phosphoric acid and flowing at 0.7 mL/min.  RI values were measured on a Carl 
Zeiss refractometer (Max Erb Instrument Co., Burbank, CA) in the same eluent as used 
for HPLC analysis. 
 
2.2.5  Plasmid DNA 
Plasmid pGL3-CV (Promega; Madison, WI) was amplified with the DH5α strain 
of E. coli (Gibco BRL; Gaithersburg, MD) and purified using the Ultramobius 1000 kit 
(Novagen; Madison, WI).  This plasmid encodes the firefly luciferase gene under control 
of the SV40 promoter. 
 
2.2.6  Polyplex Formation and Characterization 
Polyplexes were formulated by adding polycation solutions in dH2O to an equal 
volume of plasmid DNA (pDNA) in dH2O (0.05 mg/mL final pDNA concentration) and 
incubating for 30 minutes.  Desired charge ratios were achieved by using appropriate 
concentrations of polycation solution.  Each polycation was examined for its ability to 
bind pDNA through a gel electrophoresis assay using a 0.8% agarose gel (30 µg ethidium 
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bromide/50 mL TAE buffer).  Particle size and ζ-potential of polyplexes were analyzed 
using a ZetaPALS instrument (Brookhaven Instruments; Holtsville, NY). 
 
2.2.7  Cell Culture and Transfections 
BHK-21 cells were maintained at 37°C in 5% CO2 atmosphere in Dulbecco's 
Modified Eagle's Medium supplemented with 10% fetal bovine serum, 100 U/mL 
penicillin, 0.1 mg/mL streptomycin and 0.25 µg/mL amphotericin B (Gibco BRL).  For 
transfections, cells were seeded at 50,000 cells/well in 24-well plates.  Trypan blue 
exclusion was used to verify cell viability above 95%.  At one day, cells were exposed to 
200 µL serum-free medium containing 1 µg pGL3-CV plasmid pre-assembled with CD-
containing polycations at various charge ratios.  After four hours, polyplex solutions were 
removed from the cells and replaced with 1 mL regular growth medium.  For 
measurement of luciferase activity and toxicity, cells were lysed two days after 
transfection with 1X Cell Culture Lysis Reagent (Promega).  The Luciferase Assay 
System (Promega) was used to measure luciferase activity of cell lysates on a Monolight 
2010 luminometer (Becton Dickinson Biosciences; San Jose, CA).  Total protein content 
of cell lysates was assessed with the DC Protein Assay (Bio-Rad; Hercules, CA) that is a 
derivative of the Lowry assay. 
 
Supporting Information Available: MALDI-TOF spectra of CD-monomers 4a-
d and 5a-d.  This material is available free of charge via the Internet at 
http://pubs.acs.org. 
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2.3  Results 
2.3.1  Polycation Synthesis and Characterization 
β- and γ-CDs were selectively di-functionalized through a stapling reaction with 
benzophenone-3,3’-disulfonyl-imidazole (Scheme 2.1).  These intermediates react with 
various alkyl- and alkoxy-diamines to yield 3A,3B-di(aminoalkylamino)-CDs with various 
spacing groups between the carbohydrate ring and the primary amine (Scheme 2.2).  The 
difunctionalized amino-CD monomers were polymerized with DMS to give polycations 
with properties shown in Table 2.1.   
 
Polycation Polymerization
Yield (%)
dn/dc
(mL/g)
Mw (kDa) Mw/Mn Average degree
of polymerization
6a 32 0.1029 10.0 1.1 6
6b 44 0.1406 8.1 1.3 5
6c 61 0.1515 13.9 1.7 8
6d 74 0.1322 13.0 1.4 7
7a 32 0.1085 9.3 1.1 5
7b 47 0.1386 9.6 1.4 5
7c 56 0.1237 14.7 1.6 8
7d 58 0.1279 13.3 1.3 7  
Table 2.1.  Effect of cyclodextrin comonomer structure on polymerization. 
 
The choice of CD-comonomer influences the polymerization with DMS; 
polymerization yield increases with increasing distance between the cyclodextrin-ring 
and the primary amine on the CD-monomer.  Similar yield trends were observed for 
otherwise identical β- and γ-CD polycation syntheses.  CD-monomers with fewer than 
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four methylenes between the cyclodextrin and the primary amine yielded polycations 
with an average degree of polymerization (DOP) of 5 or 6, while those synthesized from 
monomers with over four spacer methylenes produced an average DOP of 7 or 8.  An 
increase in polydispersity accompanied the increase in polycation length. 
 
2.3.2  Polyplex Formation and Characterization 
 
Figure 2.2. Agarose gel electrophoresis of polycation/pDNA complexes.  For each 
polycation, complexes were formulated at charge ratios (+/-) of 0, 0.5, 1.0, 1.5, 2.0, 2.5, 
and 3.0 and run in order of increasing charge ratio (left to right) on a 0.8% agarose gel. 
 
To demonstrate polycation interaction with pDNA, polyplexes were formulated 
and run on a 0.8% agarose gel at a range of charge ratios.  Polycations 6a and 7a did not 
completely retard DNA below a charge ratio of 1.5, while 6b-d and 7b-d retarded DNA 
at charge ratios of 0.5 and above (Figure 2.2).  The diameter of polycation/pDNA 
polyplexes varied between 100 and 150 nm, while the associated ζ-potentials were all 
found to be positive (Table 2.2). 
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Polycation Particle diameter (nm) Zeta potential (mV) 
6a 121.5 ± 1.3 12.5 ± 0.3 
6b 96.4 ± 1.1 6.4 ± 1.1 
6c 107.7 ± 0.9 16.7 ± 1.7 
6d 88.2 ± 6.9 27.7 ± 1.0 
7a 124.1 ± 1.6 23.3 ± 0.5 
7b 118.6 ± 23.9 17.5 ± 3.0 
7c 153.3 ± 1.7 9.6 ± 1.1 
7d 102.9 ± 1.0 30.7 ± 1.4 
 
Table 2.2.  Particle sizing and zeta-potential of polycation/pDNA complexes formulated 
at charge ratio (+/-) of 5. 
 
2.3.3  In Vitro Transfection Efficiency  
In vitro transfection efficiency to BHK-21 cells was assessed in triplicate at 
charge ratios (+/-) of 2, 4, 6, 8, 10, 15 and 20.  Lysates of transfected cells were assessed 
for luciferase activity by measuring the relative light units (RLU) normalized by total 
protein content (Figure 2.3).   
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Figure 2.3.  Relative light units (RLU)/mg protein as a function of charge ratio for 
cyclodextin-polycation/pDNA complexes.  Complexes were formulated at various charge 
ratios and exposed to BHK cells in serum-free medium for four hours.  48 hours after 
exposure, the cells were assayed for luciferase activity.  Charge ratio of 0 indicates naked 
pDNA. 
 
Among the diaminoalkyl-CD analogues, 6a-c and 7a-c, increased spacer length 
produced greater transfection efficiency, with more pronounced enhancements between 
the a and b variants in each series.  The diaminoalkoxy-CD analogues, 6d and 7d, 
demonstrated intermediate levels of luciferase expression, below that achieved with the b 
analogues.  Generally speaking, the β-CD and γ-CD polycations with identical spacers 
produced similar luciferase gene expression. 
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2.3.4  In Vitro Cellular Toxicity 
The total protein content of cell lysates was used as a measure of polyplex and/or 
polycation toxicity (Figures 2.4 and 2.5).   
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Figure 2.4.  Cell viability to exposure of polycation/pDNA complexes at various charge 
ratios.  Cells were assayed for viability 48 hours after exposure to complexes; data were 
normalized with respect to untreated cells. 
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Figure 2.5.  Comparison of the toxicity of polycation alone to polycation/pDNA 
complexes.  Cells were exposed to polycation alone or to an equal amount of polycation 
complexed with pDNA; “charge ratio” for polycation alone merely represents amount of 
polycation.  Total protein concentrations in cell lysates were used as a measure of 
viability; data were normalized using values for untreated cells. 
 
The fractional cell survival of transfected cells was assessed by comparison to 
untransfected cells.  Amongst the charge ratios investigated, polycations 6a-c and 7a-c 
demonstrated a marked decrease in cell viability with increased spacer length; 6d and 7d 
were essentially non-toxic at the concentrations employed.  For the b and c analogues, 
cell viability decreased with increasing charge ratio and was worse for the β-CD 
polycations than for the γ-CD polycations.  The toxicity of each polycation was 
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independent of the presence of pDNA, as determined by comparison of polyplex-
transfected cells with those exposed to an equal amount of polycation alone (Figure 2.5). 
 
2.4  Discussion 
Previous studies of β-cyclodextrin-containing polycations (βCDPs) have 
demonstrated the importance of polycation structure to cellular toxicity and in vitro 
transfection efficiency.  The effect of inter-amidine distance (14) has been elucidated, as 
has the importance of using a bulky cyclodextrin instead of a smaller carbohydrate such 
as trehalose (15).  Here, we investigated the relevance of cyclodextrin ring size by 
studying otherwise identical series of β- and γ-cyclodextrin polycations.  Within each 
series, the length and character of the spacer between the cyclodextrin ring and the 
amidine charge center were varied to understand the importance of these additional 
variables in our system.  Such an approach allows the direct evaluation of the effect of 
cyclodextrin-type on in vitro transfection efficiency and cellular toxicity as well as 
providing further insights into the role of charge spacing along the polycationic 
backbone.  For in vivo application of the polycations described in this report, 
modifications are required to impart salt and serum stability.  Methodologies for 
modifying similar cyclodextrin-based polycations for in vivo use are available in our 
earlier publication (20). 
 The β- and γ-CD-based series of polycations follow remarkably similar trends in 
DOP.  DOP is found to increase with distance between the reactive primary amines of the 
CD-monomers and the cyclodextrins themselves.  As the number of methylenes between 
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the cyclodextrin and primary amine increases, an increase in DOP is observed with an 
accompanying increase in polydispersity.  All polycations shown here have an average 
DOP between 5 and 8, corresponding to an average of 10 – 16 amidine charge centers per 
polycation chain.  Assuming these differences in DOP do not significantly affect 
polycation performance, a direct correlation may be made between polycation structure 
and the observed performance. 
 Previous work demonstrated that the transfection efficiency and toxicity achieved 
with CD-containing polycations are affected by the presence of cyclodextrins and by the 
alkyl chain length between charge centers (14, 15).  Here, it is demonstrated that the 
transfection efficiency and toxicity of a related set of polycations are affected by the 
structure of the spacer separating the CD ring from the charge centers and, to a lesser 
degree, the type of CD used. 
 Diaminoalkyl-CD polycations 6a-c and 7a-c exhibit a marked increase in 
transfection efficiency as the spacer length increases, particularly with the increase from 
2 to 4 methylene units.  Dramatic differences between the a and b analogues are observed 
despite only a small change in polycation structure (a 2Å increase in distance between the 
cyclodextrin and the amidine charge center).  A smaller but significant increase in 
transfection efficiency is observed between the b and c analogues.  Polycations 6a and 7a 
gave low levels of luciferase expression that gradually increased with increasing charge 
ratio.  Optimum expression levels observed with these two polycations were of the same 
order as transfection efficiencies seen with polycations 6b, 6c, 7b and 7c at the lowest 
charge ratios.  Having reached relatively high transfection efficiencies at the lowest 
investigated charge ratios, polycations 6b, 6c, 7b and 7c did not display the steady and 
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marked increase with charge ratio seen with 6a and 7a.  Beyond a charge ratio of 6+/-, 
only 7b demonstrated a significant increase in luciferase expression. 
 The least effective polycations, 6a and 7a, are also observed to require the highest 
charge ratio to completely retard pDNA in the electrophoresis assay.  Previous work with 
CD-containing polycations has shown a correlation between relative binding efficiency 
and transfection efficiency (15).  The reduced binding efficiency associated with 
decreased spacer length may result from the bulky cyclodextrins impeding the access of 
polycation amidines to pDNA phosphates. 
 The presence of CDs in the polycation backbone has been shown to produce a 
dramatic reduction in toxicity of β-CD-containing polycations (13-16).  In part 1 of our 
study (15), 6A,6D-dideoxy-6A,6D-diamino-β-CDs were studied, while 3A,3B-dideoxy-
3A,3B-diamino-β- and γ-CDs are investigated here.  The transfection and toxicity assays 
employed in this series of papers do not indicate any advantages of functionalization of 
the CD at the C(3)-position over functionalization at the C(6)-position.  In part 1 it was 
shown that longer spacer lengths between the CD and the charge center result in 
increased toxicity; that is in agreement with the result that polycations 6a-c and 7a-c 
demonstrate an increase in toxicity as the CD-amidine distance is increased.  These 
results suggest that there is a toxicity-mediating influence of the CD on the cationic 
center, regardless of the site of CD-derivatization.  The CD may be affecting the 
interaction of the amidine charge centers with intracellular entities through its steric bulk 
and/or large sphere of hydration and thus lowering the toxicity of amidine-containing 
polycations.  The bulkiness of the CD also hinders access of polycation amidines to 
pDNA phosphates.  Since CD bulkiness and/or sphere of hydration correlate with the 
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trends in both toxicity and transfection efficiency, the observation that decreases in 
toxicity are associated with decreases in transfection efficiency and effective pDNA 
binding strength is self-consistent. 
 The diaminoalkoxy-CD polycations 6d and 7d demonstrate an intermediate level 
of transfection efficiency and insignificant toxicity.  Although this polycation pair 
provides the largest spacing between the CD and amidine residues among polycations in 
this study, the hydrophilic nature of the alkoxy spacer likely enlarges the effective 
hydration sphere around the cyclodextrin ring.  In addition, the alkoxy spacer has more 
flexibility than alkyl spacers.  These factors somehow mitigate the toxicity of polycations 
6d and 7d.  The change in transfection efficiency as a function of charge ratio is also 
intermediate relative to the diaminoalkyl-CD polycations; RLU/mg protein readings with 
polycations 6d and 7d rose gradually up to a charge ratio of 6+/-, above which no 
increase is observed. 
Each polycation produced measurable luciferase expression above background 
levels; the luciferase activities of untreated cells and cells treated with polycation alone 
are roughly 5*103 RLU/mg protein (data not shown) while the luciferase activity of cells 
treated with pDNA alone is roughly 5*104 RLU/mg protein.  For comparison, BHK-21 
cells were transfected with complexes of pDNA formulated with 25 kDa branched 
polyethylenimine or with βCDP6 (14).  Polyethylenimine complexes at an N/P of 5 were 
found to give luciferase activity of 5*109 RLU/mg protein (data not shown).  βCDP6 
complexes produced 2*108 RLU/mg protein at a charge ratio of 10+/- (data not shown). 
Here, analogous β- and γ-CD-containing polycations produced similar levels of 
gene expression, with the exception that polycations 6b and 6c outperform their γ-CD-
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containing analogues 7b and 7c at charge ratios of two and four; however, these 
differences do not persist as the charge ratio is increased.  At higher charge ratios, 
toxicity differences between the β-CD-containing polycations 6b and 6c and the γ-CD-
containing analogues become apparent, with the γ-CD-containing polycations being less 
toxic.  It is again interesting to note the correlation between enhanced transfection 
efficiency and increased toxicity. 
The peripheral diameter of γ-CD is about 17.5 Å while that of β-CD is about 15.4 
Å (19), highlighting the importance of even small variations in the CD-containing 
polycation system to in vitro performance.  Since the polycation backbone goes through 
adjacent sugar residues of the cyclodextrin ring in the case of the β- and γ-CD 
polycations discussed in this report, the linear backbone structure varies minimally 
between the two.  However, the remainder of the cyclodextrin-ring, which can be 
considered pendant to the backbone, is certainly larger in the case of γ- over β-CD. 
In part 1, Reineke and Davis showed that trehalose-based polyamidines are more 
toxic than those based on β-CD.  Here, CD-containing polycations demonstrate an 
increase in toxicity with an increase in distance between the CD and the amidine charge 
center and with a decrease in the size of the CD-ring.  Together, these results are 
consistent with the hypothesis that the size of the carbohydrate moiety and its associated 
sphere of hydration (overall increase in hydrophilicity) mitigate the toxicity of the 
amidine-based polycations. 
We have described the synthesis and characterization of a family of cyclodextrin-
containing polycations and demonstrated significant and clear effects of polycation 
structure on in vitro gene expression efficiency and cellular toxicity against BHK-21 
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cells.  The structure of diaminated cyclodextrins was found to influence both the 
molecular weight and polydispersity of polycations resulting from reaction of these 
compounds with dimethyl suberimidate.  Longer alkyl regions in the polycation backbone 
increased transfection efficiency and toxicity, while increasing hydrophilicity was 
toxicity-reducing.  Further, γ-CD polycations were shown to be less toxic than otherwise 
identical β-CD polycations. 
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3.1  Introduction 
Gene therapy promises to revolutionize the clinical treatment of countless genetic 
disorders,1 including many diseases of the liver.2  Though human gene therapy of liver 
diseases is still in its infancy, preclinical studies in animal models of disease have 
demonstrated proof of concept results in nearly all varieties of liver diseases that are 
conceptually amenable to gene therapy treatment. 
 
3.2  Liver Structure and Physiology 
The liver can be thought of as the guardian that resides between the digestive tract 
and spleen and the rest of the body.  In treating blood from the digestive system, the liver 
is handling large amounts of nutrient amino acids, lipids, vitamins and pollutant 
xenobiotics that enter the body in food and water.  In this capacity, the liver is responsible 
for metabolically regulating the excess of amino acids and ammonia derived from the 
intestine and its bacterial flora, glycogen production and storage, and processing of 
greasy compounds into water-soluble forms for excretion in bile.   
In addition to processing ingested materials, the liver has many other 
responsibilities including synthesizing the majority of the body’s total secretory protein, 
forming bilirubin and bile acids in relation to bile secretion, and removing bacteria, dying 
platelets and other particulate matter from circulation. 
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Figure 3.1.  Illustration of liver structure.  Reproduced with permission from Novartis 
Pharmaceuticals Corporation.  Circles point out mixing of blood flow from the hepatic 
artery with blood flow from the portal vein. 
 
The portal vein collects all the blood that leaves the spleen, stomach, small and 
large intestine, gallbladder and pancreas and carries it to the liver.  Approximately 75% 
of the blood flowing into the liver arrives through the portal vein,3 while the remaining 
25% of blood flow arrives via the hepatic artery and provides necessary oxygen for 
hepatic function.  Blood flowing through the portal vein and hepatic artery undergoes 
about 5 or 6 branches as it snakes through the liver, until finally blood from these two 
sources is mixed in the sinusoidal bed of the microvasculatory unit (black circles in 
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Figure 3.1 highlight mixing of blood flow from the two sources).  Sinusoids of the liver 
are specialized capillaries lined with Kupffer cells and endothelial cells that generally 
drain into central veins that ultimately empty into the inferior vena cava.  Single-cell 
thick sheets and beams of hepatocytes, which are the liver parenchymal cells, are 
surrounded on each side by sinusoidal channels and are protected by flattened endothelial 
cells that line the sinusoid and perform barrier functions.  
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Figure 3.2.  TEM image of 20 nm thick section of normal mouse liver.  ‘H’ indicates a 
hepatocyte nucleus, ‘K’ indicates a Kupffer cell nucleus, ‘R’ labels a red blood cell, ‘S’ 
labels a sinusoid and ‘E’ points to an endothelial cell lining the sinusoid. 
 
Kupffer cells (‘K’ in Figure 3.2) are highly phagocytic members of the 
reticuloendothelial system that extend directly into sinusoids and monitor blood entering 
the sinusoid for material that can be phagocytosed or endocytosed.  Kupffer cells have 
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receptors for galactose, mannose, insulin and many other ligands.4  The functions of 
Kupffer cells include phagocytosis of particulate matter, detoxification of endotoxin, 
secretion of mediators, mediation of various immune reactions, uptake and catabolism of 
lipids and glycoproteins including many enzymes, and prolongation of the life of 
hepatocytes.5   
Hepatocytes (‘H’ in Figure 3.2) are polyhedral multifaced cells with eight or more 
surfaces.  In addition to their distinctive shape, hepatocytes are characterized by large 
regular nuclei, a large number of cytoplamic organelles and a high degree of internal 
organization.  Hepatocytes possess a rich network of endoplasmic reticulum (ER) that is 
related to the well-developed secretory function of the liver6 since secretory proteins are 
synthesized selectively in the rough endoplasmic reticulum.7, 8  The most intensive 
synthesis of proteins in the liver occurs in the ER of hepatocytes,9 since the majority of 
all blood proteins originate from hepatocytes.  In addition to many other metabolic and 
catabolic functions, hepatocytes are uniquely responsible for regulating the excess of 
amino acids and ammonia from the intestine with the urea cycle, regulating lipid 
metabolism related to massive intestinal absorption of lipids and formation of bilirubin 
and bile acids in relation to bile secretion.   
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Endothelial cells
H
Figure 3.3.  TEM image of 20 nm thick section of normal mouse liver, showing liver 
sinusoidal endothelial cells separating hepatocytes from the blood vessel. 
 
Given the critical regulatory, metabolic and catabolic roles played by hepatocytes, 
it is not surprising that access to the hepatocyte cell membrane is restricted (Figure 3.3).  
The barrier between sinusoidal blood flow and access to hepatocytes is largely governed 
by capillary endothelial cells, including Kupffer cells and liver sinusoidal endothelial 
cells (LSEC).  Though LSEC are active in the uptake of macromolecular plasma solutes 
through fluid-phase endocytosis,10 the primary function of LSEC is to act as a selective 
barrier between blood and hepatocytes by restricting access to materials that can pass 
through pores in the endothelial cell lining of sinusoids.  These pores, known as 
fenestrae, measure approximately 175 nm near the portal venule, while those near the 
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hepatic venules measure approximately 147 nm.11  However, with the decreasing average 
diameter of the fenestrae, a 50% increase in their frequency is observed.  Due to this 
physical constraint, 150 nm is a generally accepted maximum size cutoff for accessing 
hepatocytes in vivo.  Turbulent flow and mechanical agitation result in minimal resistance 
to passage of appropriately sized particles through the fenestrae.12  Taken together, 
Kupffer cells and LSEC form a coordinated defense system that protects hepatocytes 
against injury from viruses, bacteria and toxins.     
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Figure 3.4.  TEM image of 20 nm thick section of normal mouse liver, showing liver 
sinusoid, liver sinusoidal endothelial cells (‘E’) and space of Disse (‘SoD’). 
 
Upon passing through the fenestrae in LSEC lining the sinusoids, material enters 
the space of Disse.  This is functional extracellular space in the liver that facilitates 
contact between the many hepatocyte microvilli that extend into this region and material 
from the blood that passed through the LSEC fenestrae.  Hepatocyte plasma membranes 
are specialized to maximize their surface area in the space of Disse with many microvilli 
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to increase the potential for contact between the hepatocyte and blood components.  
Hepatocytes are only in contact with plasma components in the space of Disse. 
 
3.3  Diseases of the Liver 
The liver is a highly desirable target for gene delivery since it is involved in many 
diseases, including both inherited and acquired genetic disorders, and it is the largest 
protein factory in the body.  Primary liver cancer is the sixth most frequent cancer 
worldwide,13 and liver transplantation is currently the best available treatment.  However, 
the stagnant levels of donor tissue, combined with increasing demand and a high risk of 
relapse, stress the need for alternative treatments.  Gene therapy can impact 
hepatocellular carcinoma directly by transducing tumor cells with apoptosis-inducing 
transgenes.  In addition to hepatocarcinoma, liver transplantation is currently the best 
approach for treating a variety of genetic diseases such as familial amyloidosis, type I and 
IV glycogen storage diseases, C protein deficiency and hemophilias A and B.14  In many 
such cases, a genetic defect exists that does not affect the liver architecture, making gene 
therapy an attractive prospect.  Hemophilia, for example, can be temporarily remedied by 
intravenous infusion of purified and recombinant factor protein, an expensive course of 
action that has potentially serious side-effects.15  Gene therapy treatment of hemophilia 
would involve delivery of the corrective gene to the parenchymal cells of the liver and 
use of their protein synthesis machinery to synthesize and secrete the defective protein, 
thus permanently restoring the ability to clot blood.  Recent promising results make 
genetic correction of hemophilic patients seem a reasonable goal, but significant 
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improvements in the vectors will be required before gene therapy becomes the commonly 
prescribed treatment of hemophilia.   
Hepatocytes, the parenchymal cells of the liver, are ideal candidates for 
expression of gene products that are desired in systemic circulation, such as hormones 
and immunomodulatory factors.  This is because of hepatocytes’ inherent ability to 
produce large amounts of protein, combined with the high volume of venous outflow 
from the liver to ensure efficient biodistribution.  In this capacity, gene therapy to the 
liver may be used to create an internal protein synthesis factory to treat diseases that may 
or may not directly impact the liver.  For example, IFN-α may confer a state of resistance 
to viral infectivity at one or more stages of virus entry or replication.  However, fewer 
than 40% of patients with chronic hepatitis B or C can be treated successfully by 
administration of interferon α (IFN-α).16  Even PEGylated IFN-α, which generates more 
sustained levels of IFN-α in the blood, is only slightly more effective.  Side effects from 
this treatment cause the withdrawal of 20% of patients from therapy, and while it is not 
conclusively understood why only a minority of patients respond to treatment, it is 
suspected that patients infected with certain viral species may require a higher amount of 
IFN-α to induce a stronger antiviral response.17  However, the high cost of this approach, 
combined with additional side-effects, has prompted research for new approaches.  Gene 
transfer of IFN-α to hepatocytes in the liver has the potential to create ongoing IFN-α 
production, a result that has been demonstrated with an adenoviral vector in a mouse 
model of viral hepatitis.  The activity of hepatitis B and C viruses, which are the main 
pathogens causing chronic liver disease, can also be inhibited by delivery of small 
interfering RNA.18 
 40
Other liver diseases, such as Gaucher’s disease, are diseases of lysosomal storage 
that primarily affect mononuclear phagocytes.  Gaucher’s disease is an inherited disease 
leading to an error of glycoshpingolipid metabolism that leads to accumulation of non-
degraded insoluble glycolipids.  Such diseases are currently treated by enzyme 
replacement therapy, but they are also good candidates for treatment by gene therapy 
targeted to specialized hepatic macrophages called Kupffer cells,19 or by enzyme 
production in hepatocytes followed by incorporation into macrophages.2   
 
3.4  Gene Delivery to the Liver 
To treat the abovementioned diseases with gene therapy, specific targeting to 
individual cell types in the liver will be required.  Many diseases call for the targeted 
delivery of nucleic acid cargo to hepatocytes in the liver; however, these cells are a 
particularly difficult target for non-viral gene therapy.  Though galactose receptors are 
almost exclusively found in the liver, the liver contains two types of galactose receptors.  
Hepatocytes abundantly express an asialoglycoprotein receptor (ASGPr) that selectively 
recognizes galactose and N-acetylgalactosamine (GalNAc) residues on small molecules, 
proteins and particles.  Experiments on rat hepatocytes revealed an estimated 1.5 x 106 
binding sites per cell.20  Kupffer cells abundantly express a galactose-particle receptor 
(GPr) that primarily recognizes galactose residues bound to solid surfaces without 
recognizing small galactosylated molecules.21   
Much work has gone towards the pursuit of hepatocyte-specific targeting of gene 
delivery particles and nanoparticles.22-24  However, seemingly contradictory results 
frequently arise due to complexities in the system, such as excess cationic charge or 
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instability in vivo.  Efficient gene transfection generally requires excess polycation in the 
formulation to counter the anionic charge of nucleic acid and permit the condensation of 
nucleic acids into compact spheres.  However, since cationic particles are nonspecifically 
adsorbed on negatively charged cell surfaces or internalized through cell-surface 
proteoglycans, it is generally difficult to separate the effect of charge-mediated uptake 
from other physicochemical properties of the system.  Generalization is also complicated 
by the broad size distribution of most gene delivery particles, allowing only rough 
correlations to be made.  There is an additional complication that is due to the 
noncovalent nature of gene delivery particles.  The meta-stable particles, held together by 
equilibrated components, are prone to instability in vivo resulting from substitution of 
formulated components with biological molecules in serum, salt-induced destabilization 
or aggregation, fusion with cellular membranes or degradation of the particle.   
The effect of particle size on cationic gene delivery has been studied in many 
systems (ref. 25 and references therein), but generalization of these results is frequently 
not straightforward for the reasons outlined above, and a variety of size limits have been 
proposed for specifically targeting the hepatic ASGPr.  While 10 nm galactosylated 
particles were found to almost exclusively target hepatocytes in the liver,26 a gene 
delivery particle that contains only a single plasmid DNA chain is expected to have a 
diameter of about 25 nm.  Therefore, 25 nm is the minimum reasonable size for gene 
delivery applications.  The relative uptake of 23 nm nanoparticles by hepatocytes and 
Kupffer cells was found to be primarily related to the density of lactose on the 
nanoparticle surface.27  23 nm nanoparticles with 60 lactose moieties on the surface 
primarily targeted hepatocytes while those with over 300 lactose moieties on the surface 
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primarily targeted Kupffer cells.  There have also been reports of 200-400 nm liposomes 
accumulating in hepatocytes following intravenous injection,28 though Kanai et al.29 
observed uptake of 240 nm lecithin-coated polystyrene beads to be primarily in Kupffer 
and sinusoidal endothelial cells.  Using neutral, targeted liposomes, Rensen et al.30 
identified an upper size limit for binding and internalization by the hepatic ASGPr as 
about 70 nm.  Targeted liposomes below this limit were effectively bound and 
internalized via ASGPr while larger liposomes were not.   
Most of the liposomes and nanoparticles discussed above were injected directly 
into the liver, via portal vein or inferior vena cava.  Though this route of administration is 
possible in humans, it is certainly not ideal.  Therefore, in my work presented here, liver 
distribution of nanoparticles will be ascertained following tail-vein injection in mice.   
In our group, we have developed linear, cyclodextrin-based gene delivery 
systems.31  By varying the conditions under which polyplexes are formulated, we can 
control various physicochemical properties of the final polyplexes, including size, surface 
charge, and density and type of ligand presented.  However, this flexibility cannot be 
maximally utilized without a set of physicochemical design constraints that have been 
optimized for the intended gene-delivery application.  We therefore set out to develop a 
model system that closely mimics the surface properties of our cyclodextrin-based gene-
delivery particles and to define design constraints that should be applied to next 
generations of that system.  We present here the development of a slightly anionic, stable 
nanoparticle-based system to guide the rational design of gene delivery to hepatocytes in 
the liver. 
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In this work, we will use galactose as a targeting ligand that is covalently bonded 
to well-defined nanoparticles to correlate their physicochemical properties with hepatic 
distribution.  Since we are delivering galactosylated particles to the liver, both Kupffer 
cells and hepatocytes must be considered primary contributors to nanoparticle uptake, 
and differentiating between uptake into hepatocytes and Kupffer cells will be critical to 
understanding the effects of ligand targeting and particle size.   
Four PEGylated polystyrene nanoparticles are synthesized, characterized and 
investigated in this work.  Chapter Four presents a discussion of the synthesis and 
characterization of the nanoparticles.  Chapter Five discusses nanoparticle uptake both in 
vitro and in vivo.  In vitro uptake is quantified in freshly isolated hepatocytes, while 
differences in in vivo uptake of the various nanoparticles following low-pressure tail-vein 
injection are visualized by TEM and immunohistochemistry.   
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4.1  Introduction 
Numerous investigators have identified the importance of carefully designing and 
controlling the properties of gene delivery systems for selectively targeting the liver.  A 
prerequisite to selective targeting is particle stability in vivo and the minimization of 
nonspecific uptake.  We and others have previously demonstrated the importance of 
PEGylation to stabilize polyplexes and to reduce their nonspecific uptake.1  Nonspecific 
uptake of particles is commonly due to rapid clearance by cells of the mononuclear 
phagocytic system2 and adhesion to the endothelial lining of the vascular system.3  Such 
undesirable uptake is minimized by surfaces with little or no protein adsorption.  In 
particular, certain proteins called opsonins interact with phagocyte receptors and promote 
recognition by scavenger cells of the reticuloendothelial organs.  Phagocytosis is 
frequently initiated by adsorption of opsonins onto the surface of particles followed by 
complement activation or other recognition, leading to internalization by macrophages 
and intracellular processing.  Dunn et al.4 have demonstrated that interaction of 
PEGylated polystyrene nanoparticles with non-parenchymal liver cells in vitro decreased 
with higher surface densities of PEG, and also resulted in longer circulation times 
following intravenous injection into rats.   
By formulating PEGylated cyclodextrin-based gene-delivery particles under 
different conditions, the size, surface charge and ligand density of the final gene delivery 
particle can all be adjusted.5  However, the power of this flexibility cannot be maximized 
without a set of physicochemical design constraints that have been optimized for the 
intended gene-delivery application.  In particular, we are interested in generating a set of 
design requirements to guide gene delivery to the liver.  In this pursuit, we describe 
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herein the development of a nanoparticle-based model system that will facilitate the 
systematic identification of relevant physicochemical properties that alter the hepatic 
distribution of nanoparticles.  Further, this nanoparticle-based model is intended to mimic 
the surface properties achievable with the linear, cyclodextrin-based gene delivery 
systems developed in our laboratory.6-9  As such, the model system will be PEGylated 
and must facilitate variation of parameters such as particle size, surface charge and ligand 
type and density.   
This chapter details the synthesis and characterization of PEGylated nanoparticles 
with tunable physicochemical properties, while the following chapter discusses the 
results of hepatic uptake experiments.  The nanoparticles described in this chapter are 
slightly anionic to minimize nonspecific uptake in vivo, and galactose will be used as a 
targeting ligand since galactose receptors in vivo are almost exclusively found in the 
liver.  In particular, four nanoparticles will be described that are appropriate for uptake 
experiments: Gal-50 and Gal-140 are galactosylated nanoparticles with diameters of 50 
nm and 140 nm, while MeO-50 and MeO-140 are methoxy-terminated 50 nm and 140 
nm nanoparticles.  Through the use of these nanoparticles, the effects of nanoparticle size 
and surface presentation of galactose on hepatic distribution in mice can be explored, and 
the results are presented in Chapter Five. 
 
4.2  Materials and Methods 
Fmoc-PEG5000-NHS was purchased from Nektar (San Carlos, CA) and used as 
received.  All other reagents and solvents were obtained from commercial suppliers and 
were used as received, unless specifically noted.  Matrix-assisted, laser 
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desorption/ionization time-of-flight mass spectroscopy (MALDI-TOF) was performed on 
a PerSeptive Biosystems Voyager DE PRO BioSpectrometry Workstation (PerSeptive 
Biosystems; Framingham, MA) in the positive ion mode using a 2,5-dihydroxy benzoic 
acid matrix.  HPLC was performed on an Agilent 1100 Series HPLC (Agilent 
Technologies; Palo Alto, CA) with a Prevail C18 5µm column (Alltech; Deerfield, IL) 
and a SEDEX Model 75 Evaporative Light Scattering (ELS) detector (Richard Scientific; 
Novato, CA).   
 
4.2.1  Synthesis of Galactose-PEG5000-amine (1, Scheme 4.1) 
4-aminophenyl β-D-galactopyranoside (1.79 g, 6.38 mmol) and Fmoc-PEG5000-
NHS (2.17 g, 0.43 mmol) were dissolved in about 16 mL of 1X PBS.  Sulfo-NHS (97 
mg, 0.44 mmol) was added, the pH was adjusted to pH 7.8 and the reaction was stirred at 
ambient temperature.  After 6 hours, EDC was added (435 mg, 2.27 mmol), and the 
reaction was stirred for an additional 48 hours.  The crude reaction mixture was dialyzed 
in 500 molecular-weight cutoff (MWCO) Float-A-Lyzers (Pierce; Rockford, IL) against 
water for two days with twice daily dialysate changes.  The solution was dried on a rotary 
evaporator at temperatures not exceeding 35OC.  Deprotection of the amine was 
accomplished by stirring the off-white product in 50 mL of 25% piperidine in DMF for 4 
hours at room temperature.  The solution was then concentrated under reduced pressure at 
temperatures not exceeding 40OC.  The viscous liquid was transferred to polypropylene 
centrifuge tubes and water was added.  Centrifugation and filtration through a 0.2 µm HT 
Tuffryn Membrane filter (VWR; West Chester, PA) resulted in complete Fmoc removal 
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from the crude reaction mixture.  The solution was subjected to extensive dialysis in 500 
MWCO Float-A-Lyzers before being lyophilized to dryness.  Purity was confirmed by 
HPLC-ELS and MALDI-TOF mass spectroscopy.  Final yield: 1.25 g, 59%. 
OHOH2C
HO
OH
O
OH NH2
FMOC-PEG5000-NHS
OHOH2C
HO
OH
O
OH NH
PEG5000
O
NH2
25% Piperidine
in DMF
EDC, Sulfo-NHS
PBS, pH 7.8
(1)
Scheme 4.1.  Synthesis of Galactose-PEG5000-NH2 (1). 
 
4.2.2  Synthesis of PEGylated-polystyrene Nanoparticles (2, Scheme 4.2) 
FITC-embedded PEGylated-polystyrene nanoparticles were synthesized by 
reaction of Fluospheres (Molecular Probes; Eugene, OR) with MeO-PEG5000-NH2 or 
Galactose-PEG5000-NH2 (1).  Two sizes of Fluospheres were used as starting materials in 
this work.  28 nm Fluospheres were used to synthesisze PEGylated nanoparticles with 
final diameters up to 60 nm, while nanoparticles up to 160 nm were synthesized by 
PEGylation of 105 nm Fluospheres.  28 nm Fluospheres were sonicated then centrifuged 
at 14,000g for 20 minutes prior to use.  All Fluospheres were sonicated immediately 
before being added to reaction vials.  Typically, 500 µL of a 2% Fluosphere suspension 
(3.21 µmol –COOH for 105 nm Fluospheres) is added to 32 mg MeO-PEG5000-NH2 (6.42 
µmol) in a 1.5 mL Eppendorf tube and mixed to dissolve the PEG.  6.3 mg Sulfo-NHS 
(Pierce) is added to each tube, and 200 mM borate buffer, pH 8.2, is added up to 1 mL 
total volume per tube.  The pH of each reaction tube is adjusted to pH 7.80 then 1.0 mg 
EDC (5.13mmol) is added to each tube and vortex mixed for 6 hours.  Purification of 50 
nm nanoparticles was accomplished by dialysis in 100k MWCO DispoDialyzers (Pierce) 
against a variety of salt solutions starting with 3 M NaCl and ending with 1X PBS.  A 
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minimum of 7 dialysate changes were performed until no free PEG was detected by 
HPLC-ELS.  Workup of 140 nm nanoparticles was accomplished by cold centrifugation 
and repeated washes in salt solutions ranging from 4 M NaCl to final resuspension in 1X 
PBS.  Bead concentrations were determined by comparison to fluorescence of known 
concentrations of as-received Fluospheres on a SpectraFluor Plus fluorescence plate 
reader (Tecan; Research Triangle Park, NC) with FITC filters (ex: 485 nm; em: 530 nm).  
Yields:  50 nm nanoparticles, typically 40%; 140 nm nanoparticles, typically 70%. 
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HO
OH
O
OH NH
PEG5000
O
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PEG5000
NH2O
COOH
COOH
COOH
COOH
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COOHHOOC
HOOC
HOOC
HOOC
HOOC
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150mM Borate buffer
pH 7.8
PEG
PEG
PEG
PEG
PEG
PEGPEG
PEG
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PEG
PEG
Galactose
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Galactose
Galactose
Galactose
(1)
(2)  
Scheme 4.2.  Synthesis of PEGylated nanoparticles (2). 
 
4.2.3  Particle Size and ζ-potential Measurements 
Colloidal particle size was determined by photon correlation spectroscopy in 150 
mM NaCl at a wavelength of 532 nm, scattering angle of 90O and refractive index of 1.59 
using a ZetaPALS instrument (Brookhaven Instruments; Holtsville, NY).  Ten 
measurements on each diluted nanoparticle sample were taken, and the mean 
hydrodynamic diameter is reported.  50 nm nanoparticles were typically measured at 
1*1013 particles/mL while 140 nm nanoparticles were typically measured at 1.5*1010 
particles/mL.  ζ-potential measurements were calculated from electrophoretic mobilities 
using the Smoluchowski equation.  Nanoparticle electrophoretic mobilities were 
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measured in 150 mM NaCl using a ZetaPALS instrument with the following conditions:  
fluid refractive index 1.334, electric field 5.41 V/cm and adjusted to a conductance of 
15.0 mS.  Three samples were each measured seven times, and the mean +/- standard 
deviation of each is reported.  
 
4.2.4  Determination of Galactose Surface Density 
Concentration of galactose on the surface of nanoparticles was determined with 
the Amplex Red Galactose/Galactose Oxidase Assay Kit (Molecular Probes; Eugene, 
OR) by comparison to standard curves of galactose in solution with unmodified 
polystyrene beads.  The reaction was allowed to proceed for a minimum of 120 minutes 
before final absorbance readings were taken due to the different rates of reaction of 
galactose oxidase with galactose in solution versus with surface-immobilized galactose.  
Details of this reaction are provided in Appendix A. 
 
4.2.5  RCA120 Lectin Agglutination 
A suspension of 5.4*1012 nanoparticles in 500 µL 1X PBS is added to 4.7*1014 
molecules of RCA120 lectin (Sigma-Aldrich; St. Louis, MO) in 500µL 1X PBS.  Each 
lectin has two identical binding sites, for a total of 9.5*1014 galactose binding sites per 
experiment.  Agglutination is monitored by measurement of absorbance at 560 nm.  After 
30 minutes, 8*1018 molecules of galactose were added in 100 µL 1X PBS to disaggregate 
the system. 
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4.2.6  TEM of Nanoparticles 
Nanoparticles in water were applied to 400-mesh, freshly glow-discharged, 
carbon-coated copper grids for 45 seconds.  After this time, excess water was removed by 
blotting with filter paper, and the sample was negatively stained with 2% uranyl acetate 
for 45 seconds before blotting.  A Philips 201 electron microscope, operated at 80 kV, 
was used to record images.   
 
4.2.7  Serum-Induced Nanoparticle Aggregation 
Mouse serum (Sigma) was incubated in 96-well plates at 37OC and 5% CO2 for a 
minimum of 2 hours before use.  5*1010 nanoparticles were added to each 90 µL of 
equilibrated sera, and aggregation was monitored by measurement of absorbance at 560 
nm at 37OC. 
 
4.3  Results and Discussion 
4.3.1 Gal-PEG5000-NH2 Synthesis and Characterization 
Fmoc-PEG5000-NHS was converted to high-purity Gal-PEG5000-NH2.  Reaction was 
driven to completion by a large excess of 4-aminophenyl β-D-galactopyranoside and an 
additional dosing of carbodiimide coupling agent, EDC.  Optimum reaction pH in NHS-
mediated peptide coupling reactions is a tradeoff between the amide formation rate and 
the rate of deactivation of the activated NHS-ester.  PEG5000-NH2 has a pKa of about 
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9.2,10 and NHS-esters on the PEG chains deactivate quickly, especially above a pH of 
about 8.  An optimal pH of about 7.8 was determined for this reaction.  While the 
concentration of Fmoc-PEG5000-NHS did not significantly influence reaction yield, 
supplementation with additional Sulfo-NHS and EDC was necessary to reactivate any 
carboxylic esters on the PEG that had hydrolyzed. 
 
Figure 4.1.  HPLC spectra of a) Fmoc-PEG5000-COOH and b) Gal-PEG5000-NH2. 
 
The purity of the final purified compound was determined by HPLC-ELS, as 
shown in Figure 4.1.  Peaks representing starting materials (Figure 4.1a) and 
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intermediates were resolved relative to the Gal-PEG5000-NH2 peak (Figure 4.1b).  Purity 
was typically greater than 98%, as determined by HPLC.   
 
Figure 4.2.  MALDI-TOF mass spectra of a) Fmoc-PEG5000-NHS and b) Gal-PEG5000-
NH2. 
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n 
Predicted 
MWFmoc-PEG-NHS  
+ Na+ 
Observed 
MWFmoc-PEG-NHS 
+ Na+ 
Predicted 
MWGal-PEG-NH2  
+ Na+ 
Observed 
MWGal-PEG-NH2 
+ Na+ 
111 5318.1 5320.4 5251.3 5250.8 
112 5362.0 5364.2 5296.3 5294.3 
113 5406.1 5408.7 5340.3 5337.9 
114 5450.1 5452.7 5384.3 5382.2 
115 5494.1 5496.7 5428.4 5426.6 
116 5538.1 5540.6 5472.4 5470.7 
117 5582.2 5585.1 5516.4 5514.7 
118 5626.2 5628.7 5560.4 5558.4 
119 5670.2 5672.8 5604.5 5602.1 
120 5714.2 5716.9 5648.5 5646.0 
121 5758.3 5761.5 5692.5 5691.0 
122 5802.3 5805.1 5736.5 5733.1 
 
Table 4.1.  Molecular weights of Fmoc-PEG5000-NHS and Gal-PEG5000-NH2 for 
incremental numbers of ethylene oxide repeat units, with sodium counterion for 
comparison to peaks of MALDI-TOF spectra. 
 
MALDI-TOF mass spectroscopy also confirmed that the reaction went to 
completion.  Primary peaks in the MALDI-TOF spectra (Figure 4.2) line up well with 
predicted molecular weights (Table 4.1) of Fmoc-PEG5000-NHS (Figure 4.2a) and Gal-
PEG5000-NH2 (Figure 4.2b), according to the following formulas:  
 
The primary population of peaks in Figure 4.2 represents [M+Na]+, while the 
subpopulation represents [M+H]+.  In addition to MALDI-TOF, the average molecular 
weight per galactose of the final product was determined to be about 5500 with the 
Amplex Red Galactose Assay Kit, as expected for nearly complete galactosylation of the 
     MWGal-PEG-NH2     =    44.026n        +        326.354        +        16.023  
            [EO repeat]     [-(CH2)2-C(O)-Gal]          [-NH2] 
    MWFmoc-PEG-NHS  =    44.026n        +        170.042        +        238.082 
             [EO repeat]   [-(CH2)2-C(O)-NHS]    [-NH-Fmoc] 
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PEG.  Thus, the molecular weight determined from this technique compares well with the 
results of MALDI-TOF analysis. 
 
4.3.2  PEGylated Nanoparticle Synthesis and Characterization 
Most previous reports of PEGylating carboxy-polystyrene nanoparticles used 1 
µm beads or larger.10-12  These large particles are relatively insensitive to reaction 
conditions, and broadening of particle size distribution was not reported.  Ploehn and 
Goodwin13 PEGylated smaller carboxy-polystyrene beads (115 and 347 nm diameter), 
but no indication was given that polydispersity was monitored during that reaction.  For 
my purpose of determining physicochemical design parameters for next generation gene 
delivery vectors, polydispersity of the final PEGylated nanoparticles should be low, 
monomodal and well-defined.  We are interested in working with nanoparticles with 
hydrodynamic diameters in the range of about 45-150 nm.  These relatively small 
polystyrene beads were found to be much more sensitive to reaction conditions than 
larger 200 nm beads, thus requiring careful study to identify reaction and purification 
conditions that resulted in pure nanoparticles with desired mean diameter, particle size 
distribution and extents of surface PEGylation.   
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Figure 4.3.  Mean hydrodynamic diameters following PEGylation of 105 nm 
Fluospheres with different reagent concentrations. 
 
The extent of PEGylation, and hence the final nanoparticle hydrodynamic 
diameter, could be controlled by varying the concentrations of PEG and EDC during 
nanoparticle synthesis, as shown by the results given in Figure 4.3.  While varying the 
concentration of PEG in the reaction simply shifted the final mean particle size without 
affecting the distribution, EDC concentrations above about 15 mM resulted in significant 
broadening of the particle size distribution.   
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By carefully controlling reaction conditions, nanoparticles could be synthesized 
with size distributions (Figure 4.4b) that closely match those of the cyclodextrin-based 
gene delivery particles (Figure 4.4a) they intend to mimic.  PEGylated nanoparticles 
larger than 105 nm can be synthesized with very tight monodisperse distributions under 
appropriate reaction conditions (Figure 4.4c).  The polydispersity of the 50 nm 
nanoparticles and polyplexes is about 0.06, while that of the 140 nm nanoparticles is 
about 0.005.  Low polydispersities such as these will allow the effect of nanoparticle size 
on biodistribution to be clearly determined.   
TEM imaging of unmodified nanoparticles validated the particle sizes measured 
by photon correlation spectroscopy (PCS).  Particle size of unmodified polystyrene 
nanoparticles was found to be in good agreement between TEM and PCS measurements.  
This was expected, given the spherical shape of the particles and hence the 
appropriateness of the Stokes-Einstein expression to relate the diffusion coefficient, 
which is measured by PCS, to the particle size.  Further, PCS measurements of particle 
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size were performed at various concentrations to ensure the accuracy of the reported 
result,14 and insignificant difference was found between these measurements.  
 
 
Figure 4.5.  TEM images of a) unmodified 105 nm Fluosphere nanoparticles and b) 
PEGylated 105 nm polystyrene nanoparticles. 
 
As seen in the TEM images in Figure 4.5a, unmodified polystyrene Fluospheres 
adopt a close-packed arrangement with direct polystyrene-polystyrene contact between 
beads, while PEGylated nanoparticles (Figure 4.5b) are separated by darkly stained PEG 
coronas and avoid polystyrene-polystyrene contact.  Further evidence of consistent 
surface PEGylation was provided by our inability to separate PEGylated polystyrene 
nanoparticles into multiple populations by hydrophobic interaction chromatography, as 
described by Moghimi.15  Moghimi also demonstrated16 that it is critical for the entire 
nanoparticle surface to be PEGylated to minimize nonspecific uptake of nanoparticles by 
the reticuloendothelial system.  It is also important that the PEGylated nanospheres be 
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well shielded to avoid aggregation in serum.  Additionally, the tight monodispersity of 
the 105 nm Fluospheres is evident from this image. 
The stability of aqueous suspensions of 220 nm PEGylated polystyrene 
nanoparticles has been shown to increase dramatically for particles with hydrodynamic 
layer thicknesses of between 10 and 15 nm.17  The impact of PEGylated surfaces is even 
more critical in salt solution, where the Debye screening length will be much shorter than 
the hydrodynamic layer thickness.  In 150 mM NaCl, for example, the Debye screening 
length is about 0.8 nm.  As such, any charge-charge repulsion that originated from the 
particle surface in pure water will no longer be influential, and the PEG layer is entirely 
responsible for sterically shielding the particles.  In the present work, 140 nm PEGylated 
nanoparticles were synthesized by grafting PEG onto 105 nm polystyrene nanoparticles, 
resulting in hydrodynamic layer thickness of slightly more than 15 nm.  As such, this 
PEG corona is expected to provide near maximum protection against nanoparticle 
flocculation.  Similarly, 50 nm PEGylated nanoparticles synthesized from 28 nm 
polystyrene have approximate hydrodynamic layer thicknesses of 11 nm.  The decreased 
hydrodynamic thickness of PEG with the same molar mass on the smaller beads can be 
explained by the increased available angular segment volume with increased surface 
curvature.18    
 
4.3.3  Availability of Galactose for Receptor Binding 
As discussed earlier, galactose is to be used as a targeting ligand on some of the 
PEGylated nanoparticles.  The surface density of galactose on the nanoparticles can be 
controlled by varying the ratio of Gal-PEG5000-NH2 to MeO-PEG5000-NH2 in the reaction.  
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Further, the overall ratio of PEG-NH2 to carboxyls enabled nanoparticles with different 
surface densities of PEG to be synthesized.   
# beads per 
experiment 
# galactose  
per bead 
pmol galactose 
per cm2 
Total # galactose 
per experiment 
Total # RCA120 
binding sites per 
experiment 
5.4E+12 1142 81.3 6.2E+15 9.5E+14 
5.4E+12 556 39.6 3.0E+15 9.5E+14 
5.4E+12 357 25.4 1.9E+15 9.5E+14 
5.4E+12 183 13.0 9.9E+14 9.5E+14 
5.4E+12 0 0 0.0E+00 9.5E+14 
 
Table 4.2.  50 nm PEGylated nanoparticles with different surface densities of galactose 
for use in RCA120 agglutination assay. 
 
Galactose moieties are presented on the surface of nanoparticles through 
attachment to a 5000 Da PEG chain.  This experiment aims to confirm that there are 
galactose moieties accessible to binding large proteins such as RCA120.  RCA120 is a 
120,000 Da lectin with two identical and independent galactose binding sites per 
molecule.19  Five 50 nm PEGylated nanoparticles were synthesized for this study with 
different surface densities of galactose, as shown in Table 4.2.   
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Figure 4.6.  Illustration of nanoparticle agglutination as a result of RCA120 lectin binding 
galactosylated nanoparticles. 
 
When RCA120 lectin is mixed with an appropriate number of galactosylated 
nanoparticles, agglutination is expected to occur.  This effect is illustrated in Figure 4.6, 
where lectins can be seen crosslinking galactosylated nanoparticles.  This crosslinked 
network scatters light, and progress of agglutination can be monitored by measuring 
absorbance at 560 nm.  Agglutination should be rapidly reversible by the addition of free 
galactose.   
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Figure 4.7.  Turbidity increase due to agglutination of galactosylated 50 nm 
nanoparticles with RCA120 lectin.  100 µL of 140 mM galactose in PBS is added at 30 
minutes. 
 
By fixing the numbers of lectin molecules and nanoparticles in all experiments, 
the effect of galactose surface density on agglutination can be seen (Figure 4.7).  
Turbidity, expressed as absorbance at 560 nm, is found to increase more quickly and to a 
greater extent for nanoparticles with a higher surface density of galactose than for 
comparable nanoparticles with lower surface densities of galactose.  For nanoparticles 
with less than about 13 pmol galactose/cm2, there are comparable numbers of galactose 
binding sites available on the RCA120 lectin and galactose available on the surface of 
nanoparticles, and no agglutination is observed.  While this result may indicate that all 
galactose molecules are not accessible to binding, the general availability of nanoparticle-
bound galactose for protein binding is confirmed.   
Add galactose 
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Add glucose
Add galactose
 
Figure 4.8.  Turbidity increase of 50 nm nanoparticle with 81.3 pmol/cm2 surface 
galactose density due to agglutination with RCA120 lectin.  100 µL of 140 mM glucose in 
PBS is added at 30 minutes then 100 µL of 140 mM galactose in PBS is added at 35 
minutes. 
 
As compared to the rapid network disruption associated with galactose addition to 
the agglutinated solution (Figure 4.7), addition of an equal volume and concentration of 
glucose does not disrupt the crosslinked network (Figure 4.8).  The only effect caused by 
addition of 100 µL of a glucose solution to the cuvette is related to dilution and is 
identical to the effect of adding 100 µL of water.  It is thus confirmed that agglutination 
is due to interaction between nanoparticle-bound galactose and RCA120 lectin molecules. 
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4.3.4  Description of Nanoparticles for Uptake Studies 
I have thus far demonstrated that nanoparticles can be synthesized with a wide 
range of physicochemical properties.  However, a select few must be chosen for in vitro 
and in vivo uptake experiments.  Four nanoparticles were selected for this role, and their 
properties are detailed in Table 4.3.   
 
Bead name Mean diameter (nm) ζ-potential (mV) 
Galactose surface 
density (pmol/cm2) 
Gal-50 51.5 -2.7 +/- 1.8 25.4 
MeO-50 53.5 -2.7 +/- 2.8 0 
Gal-140 138.1 -2.6 +/- 2.1 30.6 
MeO-140 138.7 -3.2 +/- 2.3 0 
 
Table 4.3.  Summary of physicochemical properties of the four nanoparticles to be used 
in uptake experiments. 
 
Nanoparticles with mean diameters of 50 nm and 140 nm were selected for use 
because 1) cyclodextrin-based gene delivery particles can be conveniently synthesized in 
the range of about 45 nm to about 150 nm, so the nanoparticles selected for use in the 
present study approximate the bounds of that range, 2) access to hepatocytes through the 
hepatic sinusoidal wall requires passage through endothelial-cell pores that are estimated 
at 150-200 nm,20 and 3) 50 nm is below the 70 nm cutoff that has been proposed for 
neutral liposome uptake via ASGPr.21  The effect of galactose presentation on the surface 
of the nanoparticles will be investigated for 50 nm and 140 nm nanoparticles with 
galactose surface densities of 25-30 pmol/cm2.  Galactosylated 50 nm and 140 nm 
nanoparticles are heretofore referred to as Gal-50 and Gal-140.  The equivalent 
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nontargeted nanoparticles have methoxy terminated PEG chains and will be referred to as 
MeO-50 and MeO-140. 
All nanoparticles in Table 4.3 have slightly anionic surface potentials (at the plane 
of hydrodynamic shear) to minimize nonspecific uptake.  Cationic particles are 
internalized nonspecifically through proteoglycan receptors and may stick to anionic cell 
surface membranes, while highly anionic polystyrene nanoparticles have increased 
nonspecific uptake by scavenger receptors following complement activation.22, 23  
Unmodified, carboxylated, polystyrene beads (as-received starting material) had ζ-
potentials of approximately -45 mV.  The PEGylated nanoparticles have mean ζ-
potentials of about -3 mV.  These surfaces are nearly neutral due to the combined effect 
of carboxyl conversion to amides on the nanoparticle surfaces and PEG shielding of the 
surface charge.   
  
4.3.5  Serum Aggregation of PEGylated Nanoparticles 
In order to investigate the effect of particle size on specific uptake phenomena, 
the nanoparticles must remain dispersed in the presence of serum.  They also must not 
bind serum opsonins with great affinity, as such binding has been shown to increase the 
hepatic uptake of 50 nm and 500 nm polystyrene nanoparticles.24   
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Figure 4.9.  Nanoparticle aggregation in the presence of active mouse serum.   
 
If serum proteins bind the surface of nanoparticles, crosslinking between 
nanoparticles would be expected to occur.  Since many serum proteins are anionic, 
crosslinking should be more significant for cationic nanoparticles.  For this reason, 
amino-modified polystyrene nanoparticles were used as a positive control in serum 
stability studies.  As shown by the data in Figure 4.9, amine-functionalized nanoparticles 
crosslinked quickly and extensively in active mouse serum, while the PEGylated 
nanoparticles did not.  The role of serum proteins in inducing aggregation of the amine-
functionalized nanoparticles is supported by the lack of aggregation of any of the 
nanoparticles in 1X PBS.  Despite considerable effort, aggregation of the PEGylated 
nanoparticles could not be induced under any conditions.   
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4.4  Conclusions 
The synthesis and characterization of PEGylated polystyrene nanoparticles is 
described in this chapter.  These nanoparticles have slightly anionic surface potentials to 
minimize nonspecific interaction with cells and tissue in vivo.  The synthetic scheme 
allows for the variation of mean particle size and particle size distribution through 
variation in reaction conditions.  The nanoparticle synthesis is also amenable to 
incorporation of various ligand types at tunable densities.  The synthesized nanoparticles 
were further shown to have PEGylated surfaces that resist aggregation in serum.  Finally, 
the availability of galactose to receptor binding was demonstrated by agglutination with 
RCA120. 
Having developed a flexible and versatile model system, four nanoparticles were 
synthesized specifically for the purpose of identifying design constraints to guide next 
generation gene delivery to the liver.  In preparation for in vitro and in vivo uptake 
experiments, four nanoparticles were described:  Gal-50 and Gal-140 are galactosylated 
50 nm and 140 nm nanoparticles, while MeO-50 and MeO-140 are methoxy-terminated 
50 nm and 140 nm nanoparticles.  Through the use of these nanoparticles, the effects of 
nanoparticle size and presence of galactose on the nanoparticle surface will be explored 
in Chapter Five.  
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 5.1  Introduction 
In Chapter 4, I described the synthesis and characterization of slightly anionic 
PEGylated polystyrene nanoparticles that are appropriate for in vitro and in vivo 
biodistribution experiments.  In particular, four nanoparticles were selected for in vivo 
experiments, and their properties are shown in Table 5.1. 
Bead name Mean diameter (nm) ζ-potential (mV) 
Galactose surface 
density (pmol/cm2) 
Gal-50 51.5 -2.7 +/- 1.8 25.4 
MeO-50 53.5 -2.7 +/- 2.8 0 
Gal-140 138.1 -2.6 +/- 2.1 30.6 
MeO-140 138.7 -3.2 +/- 2.3 0 
 
Table 5.1.  Summary of physicochemical properties of the four nanoparticles to be used 
in uptake experiments. 
 
In this chapter, I will discuss the in vitro hepatocyte uptake and in vivo hepatic 
distribution of the four nanoparticles described in Table 5.1.  Comparable 50 nm 
nanoparticles and 140 nm nanoparticles that differ only in the presence of galactose on 
their surfaces will allow the impact of galactose to be identified.  Galactose receptors are 
almost exclusively found in the liver, though both hepatocytes and Kupffer cells display 
galactose receptors.  Hepatocytes abundantly express an asialoglycoprotein receptor 
(ASGPr) that selectively recognizes galactose and N-acetylgalactosamine (GalNAc) 
residues on small molecules, proteins and particles.  Kupffer cells abundantly express a 
galactose-particle receptor (GPr) that primarily recognizes galactose residues bound to 
solid surfaces without recognizing small galactosylated molecules.1  While both ASGPr 
and GPr recognize galactosylated particles, uptake via these receptors is differentially 
affected by particle size.  While an upper size limit of about 70 nm has been proposed for 
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ASGPr-mediated uptake of particles,2 Kupffer cells preferentially internalize 500 nm 
particles over 80 nm particles.3  Gal-50 is below the proposed cutoff for ASGPr-mediated 
uptake, while Gal-140 is above that cutoff and may also be recognized more readily by 
the Kupffer cell GPr.  Nanoparticles were synthesized with slightly anionic surface 
potentials to minimize nonspecific interaction with cells and tissue. 
In vitro uptake experiments will make use of freshly isolated hepatocytes as 
compared to hepatocellular carcinoma cell lines to provide results that more closely 
represent hepatocyte uptake in vivo.  By their nature, carcinoma cells divide much more 
rapidly than non-oncogenic hepatocytes, and their uptake mechanisms are altered 
accordingly.  Since we are interested in studying nanoparticle uptake and distribution in 
hepatic tissue, use of primary hepatocytes will more closely approximate the uptake 
response of hepatocytes in vivo than would immortalized cell lines.  Furthermore, many 
cultured cell lines have been cultured for extended periods of time, resulting in 
heterogeneous populations of cells.  Microarray comparison of mRNA expression levels 
of whole rat liver, several rat liver cell lines and primary cultured hepatocytes indicated 
that the cell lines were most dissimilar from whole liver, and that they also differed 
significantly from primary hepatocytes.  In addition, the duration of culture had a 
profound effect on mRNA levels.  Significant differences in ethanol toxicity,4 transferrin 
internalization rate5 and ASGPr receptor levels have also been reported between 
hepatocellular carcinoma cell lines and normal hepatocytes.  For example, HepG2 cells, a 
human malignant hepatic cell line, have only about 225,000 ASGPr per cell.  Rat 
hepatocytes have approximately 550,000 ASGPr total per cell.  But while HepG2 cells 
present 87% of the total cellular ASGPr on the cell surface,6 only about 250,0007 of the 
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hepatocyte ASGPr are expressed on the cell surface while the additional 300,000 
constitute an intracellular pool.  This intracellular pool of ASGPr has been implicated in 
intracellular trafficking and processing of receptor and ligand, including a role in 
transport in the secretory pathway following ligand internalization.8  Therefore, 
immortalized cell lines such as HepG2 do not provide an ideal in vitro system to guide in 
vivo hepatic biodistribution studies, and freshly isolated hepatocytes will be used in this 
work. 
In vitro uptake into hepatocytes will be assayed both with plated cells, to compare 
the dose fraction internalized by the cells, and with suspended cells to study the kinetics 
of nanoparticle association with hepatocytes.  In vivo hepatic distribution will be 
determined by TEM and immunohistochemistry, which allow for the visualization of 
liver sections from mice that received tail-vein injections of the different nanoparticles 
described in Table 5.1.   
 
5.2  Materials and Methods 
5.2.1  Animals   
Female Balb/c mice were obtained from Charles River Laboratories (Wilmington, 
MA) and were approximately 10–15 weeks old at the time of the study.  The animals 
were fed autoclaved LabDiet 5010 (Purina Mills; St. Louis, MO) and drank reverse 
osmosis, 1ppm chlorine, autoclaved water from bottles. The mice were housed on 
ventilated racks with autoclaved nestlets and Aspen Chip bedding (Nepco; Warrensburg, 
NY) on a 13-hour light cycle at 72–76OF and 30–70% humidity.  Caltech specifically 
 80
complies with the recommendations of the Guide for Care and Use of Laboratory 
Animals with respect to restraint, husbandry, surgical procedures, feed and fluid 
regulation, and veterinary care.  The animal program at Caltech is AAALAC accredited. 
 
5.2.2  Hepatocyte Isolation 
Mouse hepatocytes were isolated from female Balb/c mice (18–25 g, 10–15 
weeks old) by the standard two-step perfusion with collagenase by the Cell Culture Core 
of the USC Research Center for Liver Diseases, as previously described.9  Briefly, mice 
were anesthetized with pentobarbital sodium (60 mg/kg), and the liver was perfused via 
the portal vein at 3 mL/min first with Ca2+ and Mg2+-free perfusion buffer (10 mM N-2-
hydroxyethylpiperazine-N’-2-ethanesulfonic acid (HEPES), 137 mM NaCl, 5 mM KCl, 
0.5 mM NaH2PO4, and 0.4 mM Na2HPO4, pH 7.2) for 3 minutes and then with perfusion 
buffer supplemented with 5 mM CaCl2 and 0.05% (w/v) collagenase (type IV; pH 7.5) 
for 3 minutes.  The liver was then carefully removed, and its capsular membrane was 
gently peeled off.  The dispersed cells, in cold Hank’s-HEPES buffer containing 0.1% 
BSA, were filtered through cotton mesh and allowed to settle.  Dead parenchymal 
hepatocytes were removed by density gradient centrifugation on Percoll (Amersham 
Biosciences; Piscataway, NJ) to give parenchymal cells of > 90% purity and >90% 
viability, as determined by trypan blue exclusion.  Appropriate numbers of hepatocytes, 
as described in the following sections, were transferred to collagen-coated dishes that 
were maintained at 37OC with 95% humidity and 5% CO2.  After one hour, the 
unattached cells were removed by aspiration, and culture medium changes were 
performed daily thereafter.  Complete hepatocyte media consisted of Dulbecco’s 
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Modified Eagle’s Medium/F12 without phenol red (Invitrogen; Carlsbad, CA), 
supplemented with L-methionine, 100 U/mL penicillin, 0.1 mg/mL streptomycin, 0.25 
mg/mL amphotericin B (Invitrogen) and 9% fetal bovine serum. 
 
5.2.3  Nanoparticle Uptake by Adherent Hepatocytes 
Following hepatocyte isolation, 100,000 hepatocytes were transferred to each well 
of collagen-coated 24-well plates.  After a minimum of 24 hours of incubation in 
complete medium, hepatocytes were incubated in OptiMem (Invitrogen) that does not 
contain any Cu2+ or Zn2+ ions for two hours prior to experimentation, to allow the hepatic 
asialoglycoprotein receptor (ASGPr) to adopt an accessible conformation and to achieve 
maximum uptake potential.10  The medium in each well was then replaced with the 
appropriate nanoparticle-containing medium, or PBS-containing medium for wells to be 
used in the preparation of standard curves.  Hepatocytes were incubated in 200 µl of 
Optimem containing 7.5*109 nanoparticles/mL for 40 minutes.  After this time, the 
medium was removed, cells were washed with cold HEPES buffer then lysed with 1X 
Cell Culture Lysis Reagent (Promega; Madison, WI).  Fluorescence of the soluble portion 
of the cell lysates was measured and compared to standard curves prepared by adding 
known numbers of beads to hepatocyte cell lysates. 
 
5.2.4  Preparation of Suspended Hepatocytes 
Following hepatocyte isolation, about 7*106 hepatocytes were transferred to a 
collagen-coated 10 cm2 dish and incubated for a minimum of 24 hours in complete 
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medium.  Hepatocytes were detached with Trypsin-EDTA (Invitrogen), spun down at 
400g for 5 minutes and resuspended at 2*106 cells/mL in complete hepatocyte media in 
50 mL polypropylene tubes, 10mL total per tube, with 40µm polypropylene Falcon Cell 
Strainers (Fisher; Hampton, NH) to minimize contamination while permitting gas 
exchange.  After incubating at 37OC and 5% CO2 overnight, hepatocytes were spun 
down, washed with HEPES buffer and resuspended in Optimem with 3% fetal bovine 
serum in polypropylene tubes.  Following 2 hours incubation in media lacking Cu2+ or 
Zn2+ ions, hepatocytes were spun down, resuspended in Optimem and aliquoted for 
experimentation.  Experimental details concerning data collection are described in the 
following section.   
 
5.2.5  Flow Cytometry Analysis of Nanoparticle Uptake Kinetics 
Single cell suspensions of 2*106 hepatocytes per mL were prepared as described 
above and kept on ice prior to analysis.  Immediately before use, cell suspensions were 
warmed to 37OC, nanoparticles were added to the FACS tube and analysis was started 
within 10 seconds.  Flow cytometry analyses were performed using a BD Bioscience 
FACSCalibur (San Jose, CA) equipped with a 488 nm argon laser and a 635 diode laser 
and Cellquest software.  Dead cells, aggregates and Kupffer cells were removed from the 
analyses by live gating on forward and side scatter.  Green fluorescence emitted by the 
beads was measured with a 530/30 nm bandpass filter.  Autofluorescent cells were 
removed by using a red channel measured by a 585/42 nm bandpass filter to gate out 
bright cells.  Flow rates were kept constant at 35 µL per minute.  Per cell mean 
 83
fluorescence from gated cells was analyzed by downloading the Cellquest list mode data 
file to FlowJo (Tree Star Inc.; Ashland, OR), gating the cells and then exporting the gated 
data to Microsoft Excel.  Mean fluorescence signals were averaged over all cells analyzed 
in five-second intervals.  The percentage of FITC-positive cells was calculated based on 
the ratio of the number of FITC-positive cells in each five-second interval to the total 
number of cells counted in that interval.  FITC mean values are normalized by the 
number of fluorescein equivalents per bead.   
 
5.2.6  Bulk Liver Uptake of Nanoparticles 
Twenty minutes after tail-vein injection of 100 µL saline containing 8*1011 
nanoparticles per 20 g mouse, mice were sacrificed and their livers were immediately 
excised, weighed and split into two comparable pieces. Each piece was then transferred 
to individual Lysing Matrix D tubes (Qbiogene; Irvine, CA) and subjected to three cycles 
of mechanical agitation in a FastPrep FP120 instrument (Qbiogene).  Cellular membranes 
were disrupted by three freeze-thaw cycles, and an additional cycle of mechanical 
agitation resulted in homogeneous liver samples that were lyophilized to dryness.  FITC 
was subsequently extracted into chloroform for comparison to a standard curve.  Standard 
curves were created by adding a known number of nanoparticles to liver pieces from 
untreated mice, followed by identical homogenization and extraction processing to the 
samples described above.  Data as shown represent tissue uptake of nanoparticles, which 
has been determined by subtracting the approximate fluorescence due to nanoparticles in 
liver blood vessels from the fluorescence of the wet liver tissue.  All experiments were 
repeated in triplicate. 
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5.2.7  TEM Imaging of Liver Tissue 
For electron microscopy, excised liver tissue was cut into 1 mm3 cubes and fixed 
in 2% glutaraldehyde in100 mM sodium cacodylate buffer (pH 7.4).  After washing in a 
sodium cacodylate buffer, the tissue was postfixed in 1% osmium tetroxide in sodium 
cacodylate buffer for 1 hour.  After rinsing, the tissue was embedded in Epon-Spurr resin.  
Thin sections of 20 nm were prepared, contrasted with uranyl acetate and lead citrate, and 
observed on a Hitachi 600 electron microscope (Hitachi Ltd.; Tokyo, Japan). 
 
5.2.8  Overlay of Fluorescence and TEM Images 
Mouse parenchymal liver cells were isolated as described above.  Cells were 
seeded at a density of 3*105 cells per collagen-coated glass cover slip in 6-well culture 
plates.  After a minimum of 24 hours incubation in complete medium, hepatocytes were 
incubated in OptiMem (Invitrogen) for two hours prior to experimentation.  Medium in 
each well was then replaced with 200 µl Optimem containing 7.5*109 nanoparticles/mL 
and incubated for 40 minutes.  Cells were then washed with HEPES buffer and fixed in 
2.5% glutaraldehyde for 2 hours at room temperature.  Glass cover slips were mounted 
with Vectashield mounting media (Vector Laboratories; Burlingame, CA).  To identify 
the same cell for light microscopy and TEM, spots were made with an ultra-fine tipped 
pen on the cell-containing cover slip.   
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5.2.9  Immunohistochemical Staining 
Mice received a 100 µL tail-vein injection containing 8*1011 nanoparticles per 20 
g mouse weight.  The injection was performed over less than five seconds using a 26-
gauge needle in all cases.  Twenty minutes after the injection of nanoparticles, mice were 
sacrificed and their livers were immediately excised, embedded in Tissue-Tek OCT 
embedding compound (Sakura Finetek USA; Torrance, CA) and stored in 2-
methylbutanol on dry ice.  Frozen liver sections were cut 12 µm thick, and two sections 
were placed on each slide for imaging.  Remaining blocks were stored at -80OC.  The 
slides were washed with PBS to remove OCT, and a perimeter was drawn around each 
pair of sections with an ImmEdge pen (Vector Laboratories).  Each section was then 
fixed with 4% paraformaldehyde and rinsed with TBS (100 mM Tris and 150 mM NaCl, 
adjusted to pH 7.4).  Slides were incubated with blocking buffer, then any biotin or 
streptavidin in the sections was blocked with the Streptavidin/Biotin Blocking Kit 
(Vector Laboratories) and rinsed with TBS.  Continuing with TBS washes between each 
step, slides were sequentially incubated with donkey blocking buffer, goat anti-ASPGR1 
antibody (Santa Cruz Biotechnology; Santa Cruz, CA), donkey anti-goat IgG-biotin 
(Santa Cruz Biotechnology) and finally QDot655 Streptavidin conjugate (Quantum Dot 
Corp.; Hayward, CA).  Following a final set of TBS washes, slides were mounted with 
Vectashield Mounting Medium with DAPI (Santa Cruz Biotechnology) nuclear stain. 
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5.2.10  Immunohistochemistry Imaging 
Images were acquired at the CHLARI Congressman Julian Dixon Cellular Image 
Core with a Leica DM RXA microscope using a HC Plan 20x/0.70NA Ph2 DIC C 
objective lens, 1.25x optovar and Koehler illumination (Leica Microsystems Inc.; 
Bannockburn, IL). A SKY/CD-300/VDS-1300 spectral imager with EasyFISH software 
(Applied Spectral Imaging, Inc.; Carlsbad, CA) was used. The 640 x 480 pixel images 
were acquired with 2 x 2 binning (1.039 um/pixel). All images acquired during a single 
session for each size nanoparticle were captured with identical exposure times and saved 
as 16-bit/channel EasyFISH files. Images were also saved as 24-bit RGB color images 
using constant slope contrast settings for each channel. Phase contrast and GFP images 
were acquired using a Chroma 41004 filter set (HQ480/40x, Q505LP dichroic, 
HQ535/50m), DAPI images were acquired using a Chroma 41001 filter set (HQ480/40x, 
Q505LP, HQ535/50m) (Chroma Technology Corp.; Brattleboro, VT) and QD655 images 
were acquired with a Leica N2.1 filter set 513832 (BP515-560, 580, LP590).  
 
5.3  Results and Discussion 
5.3.1  In Vitro Uptake Results 
Hepatocytes have access to high concentrations of amino acids and other nutrients 
from the digestive tract and endogenous protein catabolism, as well as a rich network of 
endoplasmic reticulum that enables their efficient secretory processes.11  As such, 
hepatocytes are the primary site of secretory protein synthesis in the body and are 
 87
accordingly involved in many disease states.  Hepatocytes are therefore a highly desirable 
target for gene therapy.   
Nanoparticle uptake into cultured hepatocytes can provide an initial indication of 
the effect of size and galactose targeting on hepatic uptake.  Besides the complex 
microenvironment in the liver surrounding each hepatocyte, as compared to the loosely 
packed monolayer of hepatocytes in culture, freshly isolated hepatocytes were found to 
have only 17% of their ASGPr on the cell surface12 as compared to between 40% and 
60% ASGPr presentation for hepatocytes in the liver.  After incubation at 37OC, the 
receptor distribution in isolated hepatocytes has been reported to approach 50% on the 
cell surface with the remainder associated with intracellular Golgi, microsomal and 
lysosomal membranes.13  To minimize the transient nature of these effects, hepatocytes 
were incubated in complete hepatocyte medium, as described in Materials and Methods, 
for a minimum of 24 hours prior to use. 
Nanoparticle uptake by plated hepatocytes was assayed by measuring the 
fluorescence of whole cell lysates after incubating freshly isolated hepatocytes with 
nanoparticles and washing with chilled HEPES buffer.  In all in vitro uptake experiments, 
hepatocytes were incubated for two hours in media that does not contain any Cu2+ or Zn2+ 
ions.  McAbee and Jiang10 have demonstrated that these ions result in the reversible 
accumulation of inactive ASGPr both intracellularly and on the cell surface, so 
hepatocytes were incubated at 37OC and washed in the absence of Cu2+ or Zn2+ before 
experiments were initiated. 
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Nanoparticle type % Dose in Hepatocyte Lysate 
Gal-50 21.9% 
MeO-50 9.0% 
Gal-140 1.6% 
MeO-140 1.5% 
 
Table 5.2.  In vitro uptake of nanoparticles by freshly isolated hepatocytes, as quantified 
by the overall fluorescence of cell lysates by comparison to a standard curve also using 
hepatocyte lysates. 
 
The results of nanoparticle uptake into plated hepatocytes are shown in Table 5.2.  
It is apparent that nanoparticles with 50 nm diameters are taken up to a much greater 
extent than are those with 140 nm diameter.  The presence of galactose on 140 nm beads 
has no apparent effect, with about 1.5% of each MeO-140 and Gal-140 dose being 
internalized by hepatocytes.  Galactose presentation does, however, significantly affect 
the uptake of 50 nm beads.  While about 9% of MeO-50 nanoparticles were internalized 
during the course of the experiment, greater than 20% of Gal-50 nanoparticles were 
internalized.  These results presented in Table 5.2 are consistent with the findings of 
Rensen et al.2 that hepatocytes preferentially internalize targeted liposomes with 
diameters less than about 70 nm.  In place of glycolipid-containing liposomes, the present 
work makes use of slightly anionic PEGylated nanoparticles that closely mimic the 
surface properties of stabilized gene delivery polyplexes.  Since PEGylation is commonly 
required to achieve long circulation times of nanoparticles in vivo, the results obtained 
with this system are expected to directly translate to a wide variety of gene and drug 
delivery systems. 
When formation of endocytic vesicles is accompanied by uptake of extracellular 
fluid along with any macromolecules or particles present, uptake is said to occur by fluid-
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phase endocytosis, or pinocytosis.  Vesicles resulting from pinocytosis are generally less 
than 100 nm in diameter, so it can be speculated that the fairly high uptake of nontargeted 
50 nm nanoparticles by hepatocytes in vitro may at least partially be due to pinocytosis.  
 
 
Figure 5.1.  Kinetics of nanoparticle uptake by suspended hepatocytes, as analyzed by 
flow cytometry.  a) Uptake of 50 nm and 140 nm nanoparticles are shown on the same 
scale.  b) Uptake of 140 nm nanoparticles are shown on an expanded scale. 
 
To help guide in vivo experiments and to better understand in vitro uptake, 
nanoparticle uptake kinetics were monitored with suspended, freshly-isolated 
hepatocytes, and the results are shown in Figure 5.1.  This experiment confirms the 
results obtained with plated hepatocytes.  Gal-140 and MeO-140 are taken up only 
minimally compared to the 50 nm nanoparticles (Figure 5.1a), and no difference in 
uptake was seen in 140 nm beads (Figure 5.1b) displaying galactose or methoxy on their 
surfaces.  Once again, uptake of the nontargeted MeO-50 nanoparticles does occur, but 
Gal-50 are taken up to a greater extent.  At least 10 nanoparticles were associated with 
each hepatocyte within 30 seconds of their addition to the hepatocyte suspension (data 
not shown).  This result is not unreasonable considering that ASGPr clustering has been 
observed within 15 seconds of ligand introduction,14 approximately 50% of ASGPr-
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ligand complexes are internalized within 3 minutes12,15 and that at saturation, each 
hepatocyte can take up 5*106 ligands by ASGPr per hour.7 
Following pinocytic uptake by hepatocytes in vivo, vesicles follow one of three 
distinct paths.16  About 80% of pinocytosis material is rapidly exchanged with 
extracellular fluid, about 18% is processed deeper into the cell and about 2% is secreted 
into bile.  The fraction of internalized fluid that is regurgitated back into plasma does so 
with t1/2 about 1-2 minutes in hepatocytes.  This t1/2 is considerably shorter than is seen in 
macrophages, fibroblasts or adipocytes.  Based on these uptake results, it is estimated that 
hepatocytes pinocytose the equivalent of 20% or more of their volume and at least 5 
times their plasma membrane surface area each hour.16  This high recycle rate of 
pinocytosed materials has also been confirmed with suspended rate hepatocytes,17 and the 
shape of the MeO-50 uptake curve in Figure 5.1a can be explained by this mechanism.18  
For the first 30-60 seconds of hepatocyte exposure to MeO-50 nanoparticles, uptake is 
proceeding quickly without significant nanoparticle release back into the extracellular 
fluid.  However, an average pinosome recycling time of about 1-2 minutes means that 
increasing amounts of pinocytosed material will be released after about 60 seconds until 
steady-state conditions are reached after about 200 seconds.  Under steady-state 
conditions, 80% of all pinocytosed material will be rapidly recycled while 20% will be 
retained within the cell and contribute to ongoing increases in cell fluorescence.  As such, 
an initial region of linearly increasing uptake is expected until about 30-60 seconds, at 
which time a transition will occur until another linear uptake region with a shallower 
slope is observed after about 200 seconds.  The MeO-50 kinetic uptake curve shown in 
Figure 5.1a matches this description. 
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The shape of the Gal-50 uptake curve is similar to that of MeO-50 (Figure 5.1a).  
This can be understood if the primary mechanism of uptake of Gal-50 in vitro is also 
pinocytosis, but with additional ASGPr-mediated uptake as well.  Suspended rat 
hepatocytes have been shown17 to uptake transferrin primarily by pinocytosis, despite the 
presence of a transferrin receptor on their cell surface.  Nearly 80% of transferrin uptake 
was attributed to pinocytosis, with the remainder coming through receptor-mediated 
endocytosis.  The half-time for internalization via the ASGPr is about 180 seconds,19 with 
an average time to recycle to the cell surface of about 4 minutes.6  Because of the 
similarity of these two uptake processes and the suggested dominant role of pinocytosis 
on uptake, it can be expected that Gal-50 will be internalized to a greater extent than 
MeO-50, but that the shape of the two kinetic uptake curves will be similar.  In the 
presence of Cu2+ and Zn2+ ions, uptake of Gal-50 and MeO-50 are indistinguishable (see 
Appendix D), suggesting that the difference in uptake between the two nanoparticles is 
ASGPr-mediated.   
 
5.3.2  Optimization of Experimental Conditions for In Vivo Experiments 
To allow direct comparison between all in vivo experiments, a set of experimental 
conditions was identified that maximizes hepatic uptake following injection of 
nanoparticles.  For this purpose, Gal-50 nanoparticles were utilized.  The percentage of 
the injected dose in the liver was determined by homogenizing the livers of two mice per 
set of experimental conditions and extracting the fluorescent dye in chloroform.   
Nanoparticles can be administered in a variety of ways to mice.  Since hepatic 
uptake is desired, direct injection into the liver can be accomplished via portal vein or 
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inferior vena cava.  While portal vein injections are possible in humans, unnecessary 
surgical procedures are preferentially avoided.  Therefore, the nanoparticles will be 
introduced into systemic circulation and will pass through the liver with the general blood 
flow.  Tail-vein injection in mice is the most convenient method of introducing materials 
into the mouse circulation and will be used in all in vivo experiments.  Injection of large 
volumes relative to the circulating blood volume of the mouse have been found to result 
in transiently increased cell membrane permeability20 that could obscure the effects of 
nanoparticle-size galactose presence.  Therefore, low-pressure tail-vein injections of 
nanoparticles (100 µL per 20 g mouse) will be employed in all in vivo experiments. 
 
 
Figure 5.2.  Optimization of experimental conditions for in vivo experiments by assaying 
total fluorescence of mouse liver following homogenization of liver and extraction of 
fluorophore.  a) Determination of optimal time between tail-vein injection of 
nanoparticles and liver removal.  8*1011 Gal-50 nanoparticles were injected via tail-vein 
per 20 g mouse, two mice per group, and sacrificed at the time shown.  b) Determination 
of optimal bead dose.  Mice received tail-vein injections of Gal-50 nanoparticles and 
were sacrificed 20 minutes post-injection. 
 
As shown in Figure 5.2, Gal-50 accumulates in the liver up to about 20 minutes, 
after which time its concentration decreases.  The effect of the Gal-50 dose on liver 
uptake was also investigated, over a dose range that is reasonable for nonviral gene 
delivery particles.  Based on the results of these liver uptake experiments, it was 
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determined that 8*1011 beads in 100 µL saline per 20 g mouse would be administered via 
tail-vein injection, with liver removal 20 minutes post-injection. 
 
5.3.3  Bulk Liver Uptake of Nanoparticles 
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Figure 5.3.  Overall uptake of nanoparticles into hepatic tissue.  Results are shown as 
mean ± standard deviation of three mice per group. 
 
As in the previous experiment, the uptake of nanoparticles into liver tissue can be 
determined by homogenizing the liver and extracting the fluorescent dye.  The 
comparison of bulk liver uptake of each nanoparticle is shown in Figure 5.3.  It is 
apparent that galactosylated nanoparticles are taken up to a much greater extent than are 
non-galactosylated nanoparticles, which is as expected given the unique presence of 
galactose receptors in the liver on hepatocytes and Kupffer cells.  In particular, nearly the 
entire dose of Gal-140 is found in the liver, as compared to about one-third of the Gal-50 
dose.  Concentrations of both MeO-50 and MeO-140 in the liver are quite low.  In vitro, 
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neither of the two types of 140 nm beads were internalized to a significant extent by 
hepatocytes, but it is clear that Gal-140 nanoparticles are taken up by the liver in vivo.  
As shown in the following sections, Kupffer cells are primarily responsible for Gal-140 
uptake in vivo. 
 
5.3.4  TEM Imaging Following Tail-Vein Injection of Nanoparticles 
Bulk liver uptake experiments indicated significant differences in the uptake of 
targeted and nontargeted nanoparticles, but gave no indication of the hepatic 
distributions.  TEM analysis of liver cross-sections following tail-vein injection of 
nanoparticles provided information on hepatic distribution and intracellular trafficking of 
the nanoparticles.  All images are representative of the overall hepatic distribution for 
each type of nanoparticle. 
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5.3.4.1  Hepatic Distribution of 140 nm Nanoparticles 
 
Figure 5.4 shows TEM images of a 20 nm thick section of liver tissue that had 
been exposed to Gal-140 by tail-vein injection of these nanoparticles.  The image in 
Figure 5.4a shows six hepatocytes surrounding a single Kupffer cell (marked ‘K’).  
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Hepatocytes are polyhedral cells with 8 or more surfaces and regular, round nuclei that 
represent about 60% of the cells in the liver but almost 80% of hepatic volume since they 
are the largest of the cells.  Kupffer cells are hepatic macrophages that have irregular 
nuclei and generally are located in the lumen of hepatic sinusoids adjacent to hepatocytes.  
Kupffer cells are in direct contact with the bloodstream and represent about 10% of the 
cells in the liver.   
Though isolated examples of Gal-140 in hepatocytes could be found (images not 
shown), only a few beads are found per cell in those cases, while nearly all Kupffer cells 
contain a large number of internalized beads as shown in Figure 5.4b.  This image clearly 
demonstrates Kupffer cell uptake of Gal-140, with hundreds of nanoparticles in each of 
the large phagocytic compartments (Figure 5.4c).  At 8*1011 nanoparticles injected per 20 
g mouse, approximately 50,000 nanoparticles are being injected per Kupffer cell in the 
liver.  Since the Kupffer cell galactose-particle receptor has been documented to 
endocytose as many as 4200 galactosylated particles per cell per minute,21 the large 
number of nanoparticles observed per cell is reasonable.   
Nanoparticle aggregation is not observed in Figure 5.4c, despite extremely 
concentrated conditions in the confines of phagocytic compartments.  This provides 
additional evidence that the nanoparticles are stable and do not aggregate or fall apart 
either in serum or intracellularly, confirming the results of in vitro stability assays.  The 
size stability in vivo allows the direct correlation of nanoparticle size with uptake results.   
Unlike Gal-140, MeO-140 nanoparticles are not taken up to a great extent by any 
hepatic cells.  In fact, most cells did not contain any MeO-140 beads, and few examples 
 97
could be found of aggregates of MeO-140.  However, of the cells that contained 
nanoparticles, MeO-140 were primarily internalized by Kupffer cells (images not shown).   
 
5.3.4.2  Hepatic Distribution of 50 nm Nanoparticles 
 
Figure 5.5.  TEM images of hepatocytes following tail-vein injection of a) MeO-50 and 
b) Gal-50 nanoparticles, 8*1011 per 20 g mouse.  Examples of individual vesicles are 
labeled with arrows. 
 
TEM images of liver sections following exposure to 50 nm nanoaparticles were 
quite different than those exposed to Gal-140.  Neither MeO-50 or Gal-50 were found 
concentrated in Kupffer cells, though liver that was exposed to Gal-50 had an unusually 
large number of 100-200 nm vesicles throughout the cytoplasm of most hepatocytes, as 
shown in Figure 5.5b.  As compared to hepatocytes from mice that received tail-vein 
injection of MeO-50 (Figure 5.5a), which contain occasional vesicles in the cytosol, 
hepatocytes exposed to Gal-50 contain many hundreds of clearly defined vesicles.   
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The result that Gal-140 are much more concentrated in Kupffer cells than are Gal-
50 is consistent with literature reports that Kupffer cells tend to uptake 80 nm particles 
much more slowly than they internalize 500 nm particles.3  However, identification of 
individual nanoparticles in the hepatocyte vesicles is not as clear in the case of Gal-50 as 
it was for Gal-140.  It is therefore critical to demonstrate that vesicles as shown in Figure 
5.5b do in fact contain nanoparticles.   
 
 
To confirm that the vesicles shown in Figure 5.5b contain nanoparticles, we 
endeavored to image the same cell by both fluorescence and TEM.  By carefully marking 
and photographically documenting the cell of interest, we were able to identify the same 
cell following workup for TEM.  In Figure 5.6, the capability of the technique is 
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demonstrated by imaging the same cell with light microscopy and TEM.  The nuclei and 
overall cell membrane shape, as well as relation to adjacent cells (not visible in Figure 
5.6), confirm that the same cell may be identified and imaged on separate microscopes on 
separate days.  Any slight differences in cell morphology may be attributed to the fact 
that the entire thickness of the cell is photographed with the light microscope, while only 
a thin section of about 20 nm is imaged by TEM.   
 
 
Figure 5.7.  Imaging of a hepatocyte, 24-hours post isolation that had been exposed to 
Gal-50 nanoparticles.  Comparison of a) light and fluorescence images and b) TEM 
image of the green perinuclear region on the top left side of (a).   
 
By comparing green regions seen by fluorescence microscopy of a plated 
hepatocyte in vitro with vesicle-containing regions seen by TEM, it was confirmed that 
the vesicles in hepatocytes exposed to Gal-50 in vivo contain nanoparticles.  In Figure 
5.7a, the majority of a hepatocyte is seen by fluorescence and light microscopy.  This 
plated hepatocyte was exposed to Gal-50 in vitro before being fixed with glutaraldehyde 
and imaged by confocal microscopy.  Heavy-metal staining of the cell and embedding in 
Epon resin allowed TEM to be taken of the same cell.  Since all nanoparticles used in 
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these experiments have FITC embedded in their polystyrene core, they show up as green 
in the fluorescence image (Figure 5.7a).  From this image it is apparent that the majority 
of Gal-50 beads are in the perinuclear region of the cell.  When perinuclear regions of the 
cell are magnified by TEM (Figure 5.7b), an unnaturally large number of vesicles are 
seen.  There are few vesicles in regions of the hepatocyte that do not show up green by 
fluorescence, so it is apparent that the green fluorescence originates from the large 
number of intracellular vesicles.  Isolated clusters of vesicles on TEM show up as bright 
spots by fluorescence, while clusters in close proximity, as shown in Figure 5.7b, show 
up as diffuse green regions by fluorescence.  Analogous to the situation seen in vivo 
following injection of Gal-50, individual nanoparticles cannot be easily identified inside 
vesicles, but green fluorescence is clearly originating from these vesicles.  We therefore 
conclude that Gal-50 nanoparticles are trapped within the vesicles seen by TEM. 
Hepatocytes and Kuppfer cells are not the only hepatic cells capable of 
internalizing nanoparticles.  Under the appropriate conditions, both hepatic stellate cells 
(HSC) and liver sinusoidal endothelial cells (LSEC) display phagocytic behavior.  
Following hepatic injury, hepatic stellate cells (HSC) differentiate into an activated 
phenotype that is capable of taking up 1 µm carboxylate-modified latex particles.22  
Despite liver enzyme assays indicating no toxicity associated with the nanoparticles used 
in this study, and hence no reason for HSC activation, HSC uptake of nanoparticles was 
considered and excluded based on TEM and FACS results (FACS data discussed in 
Appendix C).  We also must consider possible uptake by LSEC.  LSEC have been shown 
to nonspecifically internalize a number nanoparticles, including lecithin-coated 240 nm 
polystyrene beads,23 uncoated 240 nm and 330-800 nm polystyrene beads,24 and 12 nm 
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iron oxide nanoparticles.25  Furthermore, LSEC are indicated in the efficient ingestion 
and rapid degradation of naked pDNA in vivo and in vitro.26  Despite intense scrutiny, no 
evidence could be found of LSEC association or internalization of the PEGylated 
nanoparticles employed in this study. 
By TEM, we have thus confirmed a significant difference in hepatic distribution 
and uptake of 50 nm and 140 nm nanoparticles that present either galactose or methoxy 
moieties on their surface.  Although TEM provides a very detailed view of intracellular 
trafficking, it is limited by the small area that can be examined at a time and by lack of 
scalability, thus preventing conclusions to be drawn concerning distribution of the 
nanoparticles across the area of the liver. 
 
5.3.5  Immunohistochemistry Following Tail-Vein Injection of Nanoparticles 
To provide a more general view of the liver, an immunohistochemical staining 
(IHC) procedure was developed.  This technique is scalable in that processing may be 
done to multiple slides simultaneously.  Twenty minutes after nanoparticles were injected 
via tail-vein into mice, the liver was embedded in OCT blocks and stored in 2-
methylbutanol on dry ice.  12 µm thick liver sections were cut from the OCT blocks, 
excess OCT was dissolved away and endogenous biotin activity was blocked.  ASGPr 
was then stained red through a three-component antibody system.  Goat anti-ASGPr1 was 
used as the primary antibody to provide a target for attachment of a donkey anti-goat 
IgG-biotin antibody.  Since exogenous biotin was already blocked, incubation with 
QDot655-Streptavidin and subsequent washes permitted specific visualization of the 
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ASGPr receptor in the red fluorescence channel.  Blocking of exogenous biotin was 
critical to minimize nonspecific binding of QDot655-Streptavidin to liver tissue.  Finally, 
slides were stained with DAPI-containing VectaShield mounting media, providing blue 
staining to nucleic acids in cell nuclei. 
 
Figure 5.8.  Illustration of the staining that results from the immunohistochemical 
staining of the hepatic asialoglycoprotein receptor (ASGPr). 
In Figure 5.8, an example of the ASGPr staining pattern is drawn on a TEM 
image of normal mouse liver.  ASGPr is expressed primarily on the hepatocytic basal and 
lateral membranes, which are directed toward the perisinusoidal and pericellular spaces 
and make up about 75% of the hepatocyte circumference.  The density of ASGPr on these 
surfaces is 7- to 14-fold higher than on the apical surfaces.27,28  We would therefore 
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expect to see staining around the perimeter of sinusoids and around Kupffer cells, but 
hepatocyte-hepatocyte junctions should remain largely unstained.  However, sections 
used for IHC are 12 µm thick, or about 300 times thicker than sections used for TEM, so 
the three-dimensionality of the sinusoids must also be considered.  Liver sinusoids have 
an average diameter of about 7.3 µm,29 so it is likely that hepatocyte membranes located 
just above or below sinusoids will be partially included in the 12 µm thick IHC section.  
We would therefore expect sinusoidal endothelial cells to be included in the red-stained 
regions.  Similarly, since Kupffer cells tend to border sinusoids and sinusoid-facing 
perimeters of hepatocytes, it is to be expected that many Kupffer cells will also be stained 
red.   
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Figure 5.9.  Immunohistochemistry image of 12 µm-thick section of mouse liver 
following tail-vein injection of 8*1011 MeO-140 nanoparticles.  ASGPr is stained red, 
nuclei are blue and nanoparticles are green/yellow. 
A representative immunohistochemistry image obtained after tail-vein injection of 
MeO-140 nanoparticles into mice is shown in Figure 5.9.  In this image, a sinusoid is 
seen running from the top center of the image towards the bottom right corner before 
wrapping around a pair of hepatocyte nuclei and returning toward the top-center.  Along 
the length of this sinusoid, a large number of individual MeO-140 beads can be seen.  
The situation just described is similar to that seen in sinusoids running vertically down 
the left side and center of the image, in which the nanoparticles do not appear to be 
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aggregated.  Few examples of MeO-140 aggregation could be found, indicating that these 
beads are largely present in hepatic sinusoids and are not internalized to any great extent 
in hepatic cells.  This situation is similar to that observed for MeO-50 beads (not shown).  
No difference in nanoparticle distribution or density was observed between regions near 
the portal vein inlet to the liver and regions near the hepatic vein outlet. 
 
Figure 5.10.  Immunohistochemistry image of 12 µm-thick section of mouse liver 
following tail-vein injection of 8*1011 Gal-140 nanoparticles.  ASGPr is stained red, 
nuclei are blue and nanoparticles are green/yellow. 
The immunohistochemistry image obtained following Gal-140 injection is much 
different.  In the image shown in Figure 5.10, large aggregates of nanoparticles are 
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observed.  These aggregates show up as yellow due to bright green overlaying red.  
While both MeO-140 and Gal-140 are shown to primarily overlay sinusoidal or Kupffer 
cell regions of the liver, the massively aggregated state of Gal-140 point to uptake by 
either Kupffer or sinusoidal endothelial cells since no mechanism exists for particle 
aggregation in the sinusoids.  By TEM, no evidence of nanoparticle uptake into 
endothelial cells could be found, so we are left to conclude that the massive aggregates of 
Gal-140 nanoparticles are resident in Kupffer cells.  This result supports the conclusion 
drawn from TEM studies.  Immunohistochemistry provides the ability to image a 1-2 cm 
cross-section of liver, permitting the distribution of beads to be seen across the liver from 
portal-vein inlet to hepatic-vein outlet.  While both sized methoxy-beads are seen in 
sinusoids in similar concentrations across the liver, a somewhat higher concentration of 
Gal-140 beads are observed near the portal-vein inlet to the liver.  This observation is 
consistent with the observation that Gal-140 are taken up into cells while MeO-50 and 
MeO-140 remain largely in the sinusoids.   
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Figure 5.11.  Immunohistochemistry image of 12 µm-thick section of mouse liver 
following tail-vein injection of 8*1011 Gal-50 nanoparticles.  ASGPr is stained red, nuclei 
are blue and nanoparticles are green/yellow. 
In agreement with the TEM observations presented, immunohistochemistry on 
liver tissue from mice that received tail-vein injections of Gal-50 nanoparticles shows 
that Gal-50 are primarily internalized by hepatocytes (Figure 5.11).  In this image, a pair 
of sinusoids is seen running from the bottom right corner of the image diagonally towards 
the upper left corner.  Unlike the images taken following injection of any of the other 
beads, few Gal-50 beads are seen to overlap red-stained regions of liver.  The majority of 
nanoparticles in this image have been internalized by hepatocytes, including all 
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nanoparticles surrounded by red circles.  A few Gal-50 nanoparticles may be in 
sinusoidal spaces or in Kupffer cells, located near the center of the image and towards the 
bottom right, where the green fluorescence overlays the red ASPGr staining, but the 
majority of Gal-50 are internalized by hepatocytes. 
 
5.4  Conclusions 
In this work, I studied the hepatocyte uptake in vitro and hepatic distribution in 
vivo of four slightly anionic, PEGylated-polystyrene nanoparticles.  Slightly anionic 
surface charges are utilized to minimize nonspecific proteoglycan-mediated uptake or 
interaction with anionic cell surface membranes.  In freshly isolated hepatocytes, Gal-50 
nanoparticles are taken up to a greater extent than are MeO-50, but both 50 nm beads are 
taken up to a much greater extent than are either 140 nm nanoparticles.  However, about 
90% of the in vivo dose of Gal-140 nanoparticles is found within the liver 20 minutes 
after tail-vein injection.  TEM and immunohistochemistry images confirm that Gal-140 
are primarily internalized by Kupffer cells, though isolated examples of a few Gal-140 in 
hepatocytes can also be found.  On the other hand, Gal-50 nanoparticles are 
overwhelmingly found in vesicles throughout the cytoplasm of hepatocytes, with only 
isolated examples of Kupffer cell uptake.  Despite similar surface charge and ligand 
density, 50 nm nanoparticles are primarily found in hepatocytes while 140 nm 
nanoparticles are primarily seen in Kupffer cells.  It is therefore clear that slightly 
anionic, galactose-PEGylated nanoparticles should be about 50 nm in diameter to 
preferentially target hepatocytes while they should be about 140 nm in diameter to 
selectively target Kupffer cells. 
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 6.1  Overall Conclusions and Recomendations 
Based on the results of work presented in this report, it is apparent that the 
chemical structure and physicochemical properties of gene delivery particles affect their 
in vitro and in vivo performance.  The cyclodextrin-based gene delivery systems 
developed in our laboratory are amenable to tailoring of particle size, surface charge, and 
ligand type and density.  Through use of a nanoparticle-based model delivery system, I 
have now identified a set of parameters that enables the hepatocyte-specific targeting of 
particles in vivo.  Specifically, PEGylated 50 nm nanoparticles with 25 pmol/cm2 
galactose surface density and slightly anionic surface potentials are found to 
preferentially be internalized by hepatocytes following tail-vein injection in mice.  Given 
the difficulty of non-viral gene delivery to hepatocytes, gene delivery particles should 
now be synthesized with these properties and their in vivo hepatocyte-targeting assayed.  
Mean particle diameters of about 50 nm are attainable by formulating the particles in the 
presence of adamantane-PEG.1  Galactose surface density can be controlled by varying 
the ratio of lactose-adamantane-PEG to methoxy-adamantane-PEG during the 
formulation.  The surface charge of the particles can be controlled by incorporation of 
adamantane-PEGs that contain short anionic segments near the adamantane end.  In this 
manner, the optimized set of physicochemical properties identified with the nanoparticle-
based model delivery system may be incorporated into next-generation gene delivery 
particles. 
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6.2  Future Consideration: Increased Ligand Specificity 
In this work, a single galactose ligand was conjugated to the distal end of PEG 
chains on the surface of polystyrene beads.  While this ligand significantly altered hepatic 
distribution and uptake of the beads, resulting in effective Kupffer cell targeting of 140 
nm beads and increased hepatocyte uptake of 50 nm beads, further increases in 
hepatocyte-specificity may be desirable.   
Galactose is known to bind the hepatic asialoglycoprotein receptor with the 
relatively low affinity of approximately 4x10-4 M.2  Naturally occurring glycopeptides 
bind much stronger due to branched structure, and this ‘cluster effect’ can be mimicked 
by synthetic ligands.  The inhibitory power of the ligand can be increased significantly by 
presenting multiple galactose moieties in close vicinity,2, 3 with mono-, bi- and 
triantennary oligosaccharides capable of 50% inhibition at approximately 1 mM, 1 µM 
and 5 nM, respectively.  Stockert provides an excellent review of the asialoglycoprotein 
receptor,4 including a proposed distribution of surface receptor binding sites 
corresponding to the vertices of a triangle with sides of 15, 22 and 25 Å, in which only 
two terminal galactose residues are required for receptor recognition, with the third 
providing additional binding energy.  Studying binding between a triantennary 
glycopeptide and the rat ASGPr, Rice et al.5 reached a similar conclusion that the third 
galactose binds with less affinity than the first two.  It has been demonstrated6 that the 
spatial inter-galactose distances and the flexibility of the arm connecting galactose 
residues to the branch points significantly affects binding.  More flexible linkers resulted 
in more potent inhibitors, while spatial distances between galactose residues were best 
between 15 and 25 Å.5  A 2000-fold increase in binding affinity was found between a 
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monovalent ligand and an optimized bivalent ligand, and a 50-fold increase from the best 
bivalent to the best trivalent ligand.  Further increase to four or six galactose residues per 
molecule only increased binding slightly, likely due to an increased local concentration of 
galactose near the binding sites and interaction with an adjacent receptor.  Biessen et al.7 
investigated the effect of spacer length between the branch point and terminal sugars and 
found an at least 2000-fold increase in affinity for the asialoglycoprotein receptor 
between a trivalent ligand with only a methylene spacer and a trivalent ligand with a 20 Å 
flexible spacer. 
Galactose receptors have been found on the surface of other cells such as Kupffer 
cells, peritoneal macrophages and tumor cells.   Kichler and Schuber8 synthesized bi- and 
triantennary galactose ligands with varied distances between galactose residues and found 
that the triantennary ligand showed significantly higher affinity than the biantennary 
ligand for both the hepatocyte and peritoneal macrophage galactose receptors.  The 
dissociation constant of hepatocytes was a factor of 4 higher than that of the 
macrophages, but ideally this difference would be much greater.  Though not a primary 
concern, cluster effects are not observed in galectins,9 which are typically involved in 
cell-cell/cell-matrix interactions and growth regulation, suggesting that bi- and trivalent 
ligands will avoid interfering with these effects. 
While increased affinity for the hepatic ASGPr is desirable, a more precise goal 
may be increased specificity for hepatocytes.  In addition to increasing the valency of the 
ligand, which as discussed above has limited impact on specificity, sugar modifications 
can affect binding to ASGPr.  Terminal nonreducing D-GalNAc residues were found to 
bind hepatic ASGPr more strongly than galactose,10, 11 with an estimated 50- to 60-fold 
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enhancement in affinity.12, 13  Importantly, the peritoneal macrophage asialoglycoprotein 
binding protein (M-ASGP-BP) was shown to clearly bind Gal stronger than GalNAc,14 
though Fadden et al.15 recently observed that isolated Kupffer cell receptors for 
glycoproteins displays a slightly higher affinity for GalNAc compared to galactose.  It is 
worth mentioning that many affinity results obtained with isolated receptors generally do 
not accurately describe binding with intact receptors on the cell surface.3  In any case, the 
GalNAc ligand is significantly more selective for hepatocyte targeting than is galactose.  
Thus, an opportunity for selective targeting presents itself.  It was further demonstrated 
that a comparable tri(N-acetyl-lactosamine) ligand showed an affinity increase of about 
105 over a monovalent ligand for ASGPr, while the same ligand only enhanced binding 
by M-ASGP-BP by about 2000 times over the monovalent ligand.  It might be expected 
that such a significant difference in enhanced binding could result in improved selectivity 
of uptake. 
Due to the considerable difficulty associated with synthesizing triantennary 
ligands, it is worth considering the use of mono- or bivalent GalNAc ligands.  En route to 
synthesizing polyantennary structures, an appropriately functionalized monovalent 
GalNAc must be made.  A published scheme16 allows for the synthesis of a GalNAc 
ligand appropriate for conjugation to the distal end of PEG for conjugation to 
nanoparticles or incorporation into the nucleic acid delivery system (Scheme 6.1). 
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Scheme 6.1.  Synthesis of GalNAc-carboxylic acid ligand.16  Reagents:  (a) TMSOTf, (b) 
TMSOTf, (c) H2/Pd/EtOAc and (d) NaOMe. 
 
In place of the benzyl ester, similar protected amine compounds can be used, but the 
reaction would only be simplified slightly. 
Binding studies have compared interactions of different acylated derivatives of 
galactosamine to RHL-1, the major subunit of the rat ASGPr.13, 17  As the length of the 
acyl side chain increased from formyl to propionyl, affinity increased with the propionyl 
derivative having approximately 8 times stronger binding than the methyl derivative 
(GalNAc).  A thioacetyl derivative (GalNSAc) was found to bind slightly better than the 
propionyl derivative, while steric hindrance is suspected of reducing binding of the 
thiopropionyl derivative.  GalNSAc bound 9 times stronger than did GalNAc. 
By modifying the galactose structure, Lee18 found that the axial 4-OH of 
galactose contributes strongly to binding between Gal or GalNAc and the carbohydrate 
recognition domain (CRD) of RHL-1.  An equatorial 4-OH group is prohibitory to 
binding when the 2-acetamido group is present.  It was also determined that the lectin can 
accommodate a bulky substituent at 6-OH of galactose, indicating that substituents on 6-
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OH do not interact with the binding site, or that the binding site is spacious.  Proposed 
molecular interaction between RHL-1 and GalNAc similarly depict the 6-OH group as 
directed out of the binding cavity.  A negatively charged group at C-6 does interfere with 
binding, as do bulky aglycons α-anomerically linked to galactose. 
In a follow-up study, Lee et al.19 found that the methylene group (C-6) contributes 
to binding, with significantly decreased interaction for all compounds lacking the 
methylene group, such as those with methyl ester, carboxylic acid, amidine or amide 
substituents.  Only slight improvements, of less than 50%, could be realized by varying 
this C-5 substituent.  There appears to be a nonspecific and possibly hydrophobic 
interaction between the aglycon and the lectin, with increases in binding strength of up to 
an order of magnitude possible by modifying this unit.  In particular, there appears to be a 
strong interaction between the lectin and an amidino group on the third atom from the 
anomeric carbon, while a 4-fold improvement could be realized from large hydrophobic 
aglycons such as 6-aminohexyl.  Attachment of an acetyl group to 2-OH of methyl α-
galactopyranoside increased its inhibitory power to that of GalNAc.   
In considering additional sugar modification, there appears to be little potential 
for gain by modifying the C-5 substituent, and the methylene should be maintained.  The 
strong binding and tight cavity indicate that modification of 4-OH is likely to prove 
fruitless.  Modifications at C-2 have been made, and 7-9 times increase in binding affinity 
can be realized with propionyl or thioacetyl derivatives of GalNAc.  These sugar 
modifications may be worthwhile since they are not as laborious as other selective sugar 
modifications.  Since substituting the ether linkage for a thioether linkage did not 
significantly affect binding, opportunity appears to exist only at C-3 for additional 
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structure modification.  It is my opinion that the selective functionalization at this 
position is not immediately worth the considerable time commitment that would be 
required, since much can be learned more immediately from syntheses first of a 
monovalent GalNAc ligand, then a GalNPr ligand.  Depending on the results of in vivo 
uptake experiments with these ligands, a decision would then be made to be content with 
one of these ligands, to proceed with synthesis of the bivalent ligand or to pursue further 
sugar modification.  A priori, I believe that synthesis of a bivalent ligand will make a 
much more dramatic improvement on vector targeting than could additional sugar 
modification.  Synthesis of the bivalent ligand may not be any more difficult than 
selectively modifying galactose at the C-3 position. 
 
6.3  Future Consideration: Variation in Surface Density of Ligand 
While a single ligand may bind a single cell-surface receptor, such interaction is 
not necessarily sufficient to result in the cascade of events leading to ligand 
internalization.  It has been demonstrated that while proteins with more galactose 
residues per molecule have higher binding affinities with ASGPr,18 23 nm nanoparticles 
bearing 60 surface lactose molecules were about four times more effective at targeting 
hepatocytes than were 23 nm particles with over 300 lactose molecules.20  The 23 nm 
nanoparticles bearing over 300 lactose molecules were taken up by Kupffer cells to a 
much greater extent than were 23 nm nanoparticles bearing 60 surface lactose molecules.  
This range of 60-300 lactose per 23 nm particle corresponds to about 6-30 pmol/cm2 
galactose on the nanoparticle surface.  In the present study, surface galactose densities of 
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about 30 pmol/cm2 were employed, so additional gain may be realized by decreasing the 
surface density of galactose.   
With 27 nm liposomes, Sliedregt et al.21 found that at a loading ratio of 5% (w/w) 
of glycolipid targeting molecule, particles were primarily processed by the hepatic 
ASGPr.  But at a targeting loading ratio of 50% (w/w) resulted primarily in Kupffer cell 
uptake.  However, the increased specificity of GalNAc for hepatocytes appears to 
increase the loading window that still results in hepatocyte targeting,22 with further 
benefit coming from incorporation of a triantennary GalNAc ligand into the liposome.  
Despite the decreased concern of Kupffer cell uptake with GalNAc ligand, there may still 
be an optimal ligand density on the surface to give maximum uptake into hepatocytes 
through the entire volume of the liver.  Once GalNAc ligands are incorporated into the 
system, and optimal particle size for hepatocyte uptake is nailed down, the effect of 
ligand density could be investigated.  
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Appendix A:  Galactose Surface Concentration Determination 
As described in the Methods and Materials section of Chapter 3, the surface 
density of galactose on the nanoparticles was determined with the Amplex Red 
Galactose/Galactose Oxidase Kit from Molecular Probes.  However, comparison to a 
galactose standard curve at 10-30 minutes, as suggested in the kit, did not yield 
reproducible results.   
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Figure A.1.  Calculated surface density of galactose on nanoparticle surfaces by 
comparison to a standard curve of free galactose in solution. 
 
As shown in Figure A.1, the calculated surface density of galactose varied 
considerably over time, as determined by comparison to a standard curve of 6 different 
concentrations of galactose in solution.  This difference can be explained by the high 
local concentration of galactose on the nanoparticle surface.  After diffusing to find a 
single nanoparticle, the galactose oxidase enzyme is able to quickly jump from galactose 
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to galactose on the nanoparticle surface.  However, in solution, the enzyme must diffuse 
much longer distances between galactose molecules at every jump.  Therefore, reaction 
on the nanoparticle surface occurs much more quickly than does oxidation of galactose in 
solution.  Since the rate of oxidation of galactose ultimately defines the measured 
absorbance of the solution, an artificially high concentration of galactose on the 
nanoparticle surfaces is initially measured.  Only after about 120 minutes does the 
calculated surface density of galactose level off.  The reported values of galactose surface 
density are taken as averages of multiple measurements at times greater than 120 
minutes.  Glucose was found to have no reactivity in this system, and methoxy-
terminated nanoparticles of all sizes were correctly identified at all times as having no 
galactose on their surfaces. 
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Appendix B:  Nanoparticle Exocytosis by Freshly Isolated, Cultured Hepatocytes 
Nanoparticle 
type 
% Dose in Lysate, 
Warm Wash 
% Dose in Lysate,  
Cold Wash 
Gal-50 14.9% 21.9% 
MeO-50 7.7% 9.0% 
Gal-140 0.9% 1.6% 
MeO-140 1.0% 1.5% 
 
Table B.1.  Effect of wash buffer temperature on dose of nanoparticles following 
incubation with freshly isolated hepatocytes.  After removal of nanoparticle-containing 
media, wash buffer of either 37OC or 2OC was incubated on the plated cells for 5 minutes.  
Wash buffer was then removed, cells were lysed and fluorescence of cell lysate was 
compared to standard curves of nanoparticles in unadulterated hepatocyte lysate. 
 
As shown in Table B.1, exocytosis of nanoparticles appears to be a significant 
concern.  While about 22% of the Gal-50 dose was present in hepatocytes following a 5 
minute wash with cold buffer, only about 15% of the dose was present after a similar 
wash with warm buffer.  Similar behavior was seen in all other nanoparticles studied. 
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Figure B.1.  Kinetics of exocytosis of nanoparticles from suspended freshly isolated 
hepatocytes. 
 
In Figure B.1, the rapid rate of exocytosis of nanoparticles is seen.  In this 
experiment, hepatocytes were incubated at 37OC with nanoparticles for 30 minutes.  
Nanoparticle-containing media was then removed, hepatocytes were resuspended in fresh 
media and data collection was begun within 10 seconds.  Despite the relatively low 
uptake of 140 nm nanoparticles by suspended hepatocytes, the kinetic exocytosis profiles 
of all four nanoparticles collapse onto one curve.  Based on this result, it may be 
suggested that the primary mechanism of exocytosis of all four nanoparticles by 
suspended hepatocytes is similar. 
Rudolph and Regoeczi,1 working with suspended rat hepatocytes, observed a 
rapid release of pinocytosed material, while material internalized via receptor-mediated 
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endocytosis was released more slowly.  Within 7.5 minutes, only about 20% of the dose 
internalized by pinocytosis remained.  This is not dissimilar from the results shown in 
Figure B.1 with about 35% of the dose remaining after that time.   
Binding and endocytosis of ASGPr appear to be maintained through a continuous 
reutilization of plasma membrane receptors rather than through their replacement from 
the intracellular receptor pool that is known to exist for ASGPr.2  Even if Gal-50 are 
being internalized by an ASGPr-mediated mechanism, there is a legitimate concern then 
that the ligand may be caught in this short-circuit pathway of receptor recycling that has 
been shown to occur with a t1/2 of about 4 minutes.3  Independent of the mechanism, 
quantitation of nanoparticle uptake by hepatocytes in vivo is complicated by such rapid 
exocytosis.  
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Appendix C:  Isolation of Non-Parenchymal Liver Cells after Nanoparticle Injection 
Unlike the rapid exocytosis observed following nanoparticle uptake by 
hepatocytes, no evidence of nanoparticle exocytosis was observed in cultured Kupffer 
cells.  This result is in agreement with a literature finding1 that after phagocytosis of 
carbon particles, Kupffer cells entered a physiological state where receptor recycling does 
not take place.  We may therefore consider isolating Kupffer cells following tail-vein 
injection of nanoparticles without concern of misrepresented uptake data due to 
nanoparticle exocytosis.   
Quantification of uptake by individual cell-types in the liver would facilitate 
identification of relationships between nanoparticle structure and in vivo response.  Along 
these lines, we injected 8x1011 beads per 20 g mouse, then isolated non-parenchymal 
cells after 20 minutes.  Non-parenchymal liver cells were isolated by the Non-
parenchymal Liver Cell Core of the Research Center for Alcoholic Liver and Pancreatic 
Diseases, as previously published.2  FACS was performed at the Flow Cytometry Core at 
the USC Health Sciences campus.   
 
Bead Type % FITC-positive  
Kupffer cells 
% FITC-positive  
Hepatic stellate cells 
Gal-50 29.30 +/- 4.72 <1% 
MeO-50 3.37 +/- 0.49 <1% 
Gal-140 76.88 +/- 3.03 <1% 
MeO-140 28.76 +/- 3.01 <1% 
 
Table C.1.  Fraction of nanoparticle-containing Kupffer cells after their isolation from 
mouse livers that were exposed to nanoparticles by tail-vein injection of 8*1011 
nanoparticles per 20 g Balb/c mouse. 
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In Table C.1, we can clearly see that Gal-140 are primarily taken up by Kupffer 
cells, and that nearly all Kupffer cells contain Gal-140.  Though almost 30% of Kupffer 
cells contain MeO-140 nanoparticles, the mean fluorescence of MeO-140-containing 
Kupffer cells was less than 10% of the mean fluorescence of Gal-140-containing Kupffer 
cells.  Further, a wide distribution of fluorescence values were seen following Kupffer 
cell exposure to Gal-140, while a narrow distribution was seen in Kupffer cells exposed 
to MeO-140.  Therefore, we see that not only is the percentage of Kupffer cells that 
phagocytosed MeO-140 much lower than the percentage that phagocytosed Gal-140 
(29% versus 77%), the number of beads taken up by the average Kupffer cell is also 
much lower for MeO-140. 
In this experiment, the percent of FITC-positive Kupffer and Hepatic stellate cells 
is determined after tail-vein injection in mice.  The percentage of FITC-positive 
hepatocytes could not be determined similarly due to rapid exocytosis of nanoparticles 
from hepatocytes.  Additionally, because the data shown in Table C.1 for 50 nm and 140 
nm nanoparticles were collected months apart with different instrument settings, it is 
impossible to accurately compare the mean fluorescence values of 50 nm and 140 nm 
nanoparticles.  Including all liver cell types, each injected dose contains approximately 
4000 nanoparticles per cell, so it is conceivable to have 100% FITC-positive cells, with 
each cell having internalized 40 nanoparticles, and only 1% total uptake.  Therefore, 
direct comparison of the data presented in Figure C.1 to the data presented in Figure 5.3 
is not possible. 
We also see that almost 30% of Kupffer cells exposed to Gal-50 have internalized 
some of the nanoparticles.  By microscopy, we saw that hepatocytes were the primary site 
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of internalization of Gal-50, but clearly there is room for increased specificity.  In the 
future directions section of this report, the next steps in ligand synthesis is discussed. 
FACS analysis was also performed on Hepatic stellate cells, but no evidence of 
nanoparticle internalization was seen (Table C.1).  
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Appendix D:  Effect of Nanoparticle Dose on Uptake by Suspended Hepatocytes 
As described in the Methods section, hepatocytes were detached from 10 cm2 
plates and resuspended in colorless, complete hepatocyte media.  Following overnight 
incubation at 37OC and 5% CO2, the cells were spun down, resuspended in colorless 
media without FBS or Cu2+ or Zn2+ ions and incubated for an additional two hours.  The 
cells were then washed, resuspended and counted, filtered and distributed to individual 
tubes for experimentation.  Following appropriate incubation with beads, cell suspensions 
were transferred to FACS tubes on ice. 
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Figure D.1.  Effect of nanoparticle dose on uptake into suspended hepatocytes, in media 
containing Cu2+ and Zn2+ ions. 
 
The importance of Cu2+ and Zn2+ ion-removal prior to uptake experiments is 
shown by the results in Figure D.1.  In that experiment, suspended hepatocytes were 
maintained in colorless D-MEM/F-12 media (Invitrogen) until the experiment was begun.  
Gal-50 or MeO-50 nanoparticles were added to the hepatocytes in D-MEM/F-12 medium 
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and incubated for 45 minutes at 37OC under 5% CO2 atmosphere to allow equilibrium to 
be reached.  The presence of galactose on the nanoparticle surface has no impact on 
uptake relative to the nontargeted equivalent, MeO-50.   
 
 
Figure D.2.  Effect of bead concentration on mean fluorescence of suspended primary 
hepatocytes.    
 
Incubation of hepatocytes in Opti-MEM media that does not contain Cu2+ or Zn2+ 
ions for two hours, followed by cell wash in Opti-MEM, allows the impact of galactose 
to be seen (Figure D.2).  The strong linear correlation between FITC mean and 
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nanoparticle dose is in agreement with the hypothesis that pinocytosis is the primary 
mechanism of nanoparticle uptake by suspended hepatocytes.  However, this data alone 
does not conclusively single out any mechanism of uptake.  In pinocytosis, the rate of 
uptake is directly proportional to the concentration of macromolecules or particles in the 
extracellular fluid, but rates of pinocytosis may be 20,000 times slower than uptake via 
ASGPr-mediated endocytosis.1  Free galactose in solution with nanoparticles was not 
found to significantly impact uptake results. 
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